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List  of  Abbreviations:  
CD   Caesarean  delivery  
SBP   Systolic  blood  pressure  
DBP   Diastolic  blood  pressure  
MAP   Mean  arterial  pressure  
SVR   Systemic  vascular  resistance  
HR   Heart  rate  
SV   Stroke  volume  
CO   Cardiac  output  
IUGR   Intra-­uterine  growth  restriction  
SFlt-­1   Soluble  fms-­like  tyrosine  kinase-­1  
sEng   Soluble  endoglin  
VEGF   Vascular  endothelial  growth  factor  
PlGF   Placental  growth  factor  
TGF-­b   Transforming  growth  factor-­  beta  
NRFHRT   Non-­reassuring  fetal  heart  rate  trace  
SD   Standard  deviation  
IQR   Interquartile  range  
CI   Confidence  interval  
ASA   American  Society  of  Anesthesiologists  
BE   Base  excess  
UA   Umbilical  arterial  
UV   Umbilical  venous  
UA/UV   Ratio  of  umbilical  arterial  to  venous  
PO2   Partial  pressure  of  oxygen     
PCO2   Partial  pressure  of  carbon  dioxide  
(A-­V)  PCO2   Arteriovenous  PCO2  difference  
RDBT   Randomized  double  blinded  trial  
aOR   Adjusted  odds  ratio  
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PART  A:  STUDY  PROTOCOL  
As  approved  by  the  Departmental  Research  Committee,  the  Human  Research  Ethics  
Committee,  and  the  Professional  Masters  Committee  of  the  University  of  Cape  Town.  
Introduction  
Hypotension  remains  a  common  clinical  problem  after  induction  of  spinal  anaesthesia  for  
caesarean  delivery.1      Despite  multiple  techniques  for  preventing  spinal  anaesthesia-­
induced  hypotension,  including  fluid  preloading,  left  uterine  displacement  and  
administration  of  vasoactive  drugs,  no  consistently  successful  method  for  prevention  and  
treatment  has  been  described.    Hypotension  results  in  significant  morbidity  (nausea  and  
vomiting  in  the  mother;;  fetal  and  neonatal  metabolic  acidosis).  In  terms  of  prevention  and  
treatment,  ephedrine  has  traditionally  been  the  vasopressor  of  choice.  This  preference  
was  based  on  animal  studies  which  showed  that  ephedrine  maintained  cardiac  output  
and  uterine  blood  flow  while  direct  acting  vasoconstrictors  (such  as  phenylephrine)  
decreased  uteroplacental  perfusion.  However,  animal  studies  cannot  necessarily  always  
be  applied  to  humans  and  recent  clinical  trials  have  demonstrated  that  phenylephrine  
has  at  least  similar  efficacy  to  ephedrine  for  preventing  and  treating  spinal  hypotension  
and  in  addition,  it  is  associated  with  an  improved  fetal  acid  base  status.  2-­4    The    majority  
of  these  trials  have  been  performed  in  healthy  parturients  undergoing  elective  caesarean  
delivery.    
Preeclampsia  complicates  approximately  5%  of  pregnancies  and  is  a  significant  cause  of  
maternal  and  fetal  morbidity  and  mortality.  
Maternal  and  fetal  death  from  preeclampsia  is  a  significant  risk,  and  sequelae  of  the  
disease  include  placental  abruption,  intracranial  haemorrhage,  cardiac  failure,  and  multi-­
organ  failure  in  the  mother  and  intra-­uterine  growth  restriction  and  preterm  delivery  of  the  
fetus.    Preeclampsia  is  a  pregnancy-­specific  syndrome  which  occurs  after  the  20th  week  
of  gestation.    Criteria  for  diagnosis  of  severe  preeclampsia  include  an  increased  blood  
pressure  (defined  as  systolic  blood  pressure  >160  mmHg  or  diastolic  blood  pressure  
>110  mmHg  in  a  woman  previously  normotensive)  accompanied  by  proteinuria  (urine
dipstix  3+  or  worse).
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Many  preeclamptic  patients  require  caesarian  delivery  of  the  infant.    These  patients  often  
have  uteroplacental  insufficiency.    Neuraxial  anaesthesia  is  preferred  for  caesarean  
delivery,  due  to  problems  related  to  management  of  the  airway.    Spinal  anaesthesia  has  
become  the  preferred  technique  during  the  past  15  years.    Recent  studies  have  
demonstrated  that  preeclamptic  patients  may  experience  less  hypotension  after  spinal  
anaesthesia  than  their  healthy  counterparts,5;;6  and  hypotension  tends  to  be  less  severe  
in  patients  with  marked  hypertension.    A  modest  lowering  of  the  blood  pressure  has  been  
shown  to  represent  afterload  reduction,  which  is  in  principle  desirable  in  these  patients.7    
However,  severe  hypotension  does  occur  after  spinal  anaesthesia  in  some  cases,  and  
this  may  further  compromise  a  fetus  already  at  high  risk.    In  only  one  observational  study  
has  phenylephrine  been  studied  for  the  treatment  of  spinal  hypotension  in  patients  with  
preeclampsia.    Small  doses  reversed  hypotension  and  restored  the  systemic  vascular  
resistance.7    Thus,  the  primary  aim  of  our  study  is  to  compare  the  use  of  bolus  ephedrine  
and  phenylephrine  for  the  treatment  of  spinal  hypotension  in  preeclamptic  patients  with  a  
non-­reassuring  fetal  heart  trace,  undergoing  caesarean  delivery.    The  primary  outcome  
variable  in  the  study  will  be  umbilical  arterial  base  deficit.      
Patients  and  methods  
Preeclampsia  is  diagnosed  if  the  diastolic  blood  pressure  after  20  weeks’ gestational  age  
is  greater  than  or  equal  to  90  mmHg  on  two  separate  occasions  at  least  4  hours  apart,  
and  proteinuria  of  2+  on  urine  dipstix  in  two  clean  midstream  samples  taken  at  least  4  
hours  apart,  or  greater  than  or  equal  to  300  mg  protein  per  24  hours.    Preeclampsia  is  
regarded  as  severe  if  the  systolic  blood  pressure  exceeded  160  mmHg  and/or  the  
diastolic  blood  pressure  exceeds  110  mmHg,  obtained  on  at  least  two  separate  
occasions,  or  if  the  patient  has  symptoms  of  imminent  eclampsia  (namely  severe  
headache,  visual  disturbance,  epigastric  pain,  hyperreflexia,  dizziness  and  fainting,  or  
vomiting)  and  proteinuria  on  urine  dipstix  is  3+  or  worse.          
Informed  written  consent  will  be  taken  wherever  possible  when  the  diagnosis  is  made  
after  admission  to  hospital.    In  some  cases,  it  may  be  necessary  to  obtain  consent  closer  
to  the  time  of  decision  to  proceed  to  caesarian  delivery.    The  study  will  commence  after  
the  approval  of  the  Health  Science  Faculty  Human  Research  Ethics  Committee  
(HSFHREC)  of  the  University  of  Cape  Town,  and  will  be  performed  at  the  New  Groote  
Schuur  Hospital  Maternity  Centre.    One  hundred  and  sixty  patients  with  severe  
preeclampsia  requiring  urgent  caesarean  delivery  under  spinal  anaesthesia,  will  be  
recruited  into  this  randomised  trial,  which  will  examine  the  effects  of  bolus  ephedrine  or  
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phenylephrine  administered  in  response  to  spinal  hypotension,  on  umbilical  arterial  base  
deficit.  
Maternal  exclusion  criteria  will  be:  patient  refusal,  any  contra-­indication  to  spinal  
anaesthesia,  body  mass  index  greater  than  40  kg/m2,  clinical  signs  of  hypovolaemia,  
abruptio  placentae,  placenta  praevia,  coagulation  abnormality,  thrombocytopaenia  
(platelet  count  <  75x109/L),  pulmonary  oedema,  local  or  generalized  sepsis,  spinal  
deformity,  cord  prolapse,  prior  non-­obstetric  abdominal  surgery,  more  than  2  previous  
caesarean  deliveries,  or  patients  who  are  HIV  positive  and  have  AIDS-­defining  disease  
at  the  time  of  recruitment.    Fetal  exclusion  criteria  will  be  persistent  fetal  bradycardia  or  
any  other  fetal  condition  contraindicating  spinal  anaesthesia,  gestational  age  <  28  weeks,  
estimated  fetal  weight  <  900  g,  and  twin  pregnancy.    
Should  any  spinal  anaesthetic  take  longer  than  20  minutes  to  perform,  the  patient  will  
receive  general  anaesthesia,  and  the  data  recorded  as  a  failure  of  the  technique.      
Prior  to  being  recruited  to  the  study,  the  antepartum  management  will  be  according  to  the  
established  protocol  of  our  institution:  if  the  patient  is  in  established  labour,  an  
intravenous  line  will  be  inserted,  and  a  balanced  crystalloid  solution  administered  at  less  
than  120  mL  per  hour.    Patients  not  in  labour  will  be  allowed  free  oral  fluids.    Seizure  
prophylaxis  will  be  administered  to  patients  with  severe  preeclampsia,  consisting  of  
magnesium  sulphate  (MgSO4),  administered  as  a  loading  dose  of  4g  intravenously,  
followed  by  1g  hourly  intravenously.    Dihydrallazine  will  be  administered  intravenously  as  
a  vasodilator,  for  additional  blood  pressure  control  against  a  standardized  protocol.    Prior  
use  of  other  agents  (alphamethyldopa,  morphine  and  dexamethasone)  will  be  recorded.  
When  a  decision  is  made  to  proceed  to  caesarean  delivery,  the  patient  will  be  placed  in  
the  left  lateral  position  before  transfer  to  theatre,  and  will  receive  40%  oxygen  by  face-­
mask.      
All  patients  will  receive  30  ml  sodium  citrate  orally  in  theatre,  as  well  as  1  g  cefazolin  IV  
prior  to  induction  of  spinal  anaesthesia.    Monitoring  will  consist  of  electrocardiograph,  
non-­invasive  blood  pressure  and  pulse  oximetry  in  all  patients.    Baseline  mean  arterial  
pressures  will  be  recorded  as  the  mean  of  two  non-­invasive  blood  pressure  readings  not  
differing  by  more  than  10%,  taken  in  the  5  minutes  prior  to  induction  of  spinal  
anaesthesia,  measured  at  rest  in  the  left  lateral  position.    After  measurement  of  baseline  
blood  pressure,  the  target  value  for  administration  of  vasopressor  will  be  calculated.    
Thereafter  a  preload  of  300  mL  hydroxyethyl  starch  (Voluven  ®)  will  be  rapidly  
administered.    Haemodynamic  data  will  be  recorded  every  minute  after  spinal  
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anaesthesia  until  45  minutes  thereafter  or  until  the  end  of  surgery  if  the  duration  is  longer  
than  45  minutes.      
The  management  of  spinal  anaesthesia  will  be  as  follows:    
All  patients  will  receive  2.0  – 2.2  ml  of  hyperbaric  0.5%  bupivacaine,  with  10  µg  of  
fentanyl,  administered  in  the  sitting  position  at  the  L3/4  interspace  in  the  absence  of  
uterine  contractions.    After  20  seconds  in  the  sitting  position,  patients  will  be  positioned  
supine,  with  15  degrees  of  left  lateral  tilt,  to  minimise  aortocaval  compression.    Block  
height  will  be  assessed  using  cold  sensitivity  to  ethyl  chloride  spray,  and  surgery  will  
commence  when  a  block  level  of  T4  is  achieved.    All  mothers  will  receive  40%  oxygen  by  
face-­mask.    The  management  of  hypotension  will  be  as  follows:  
Patients  will  be  randomised  by  sealed  envelope  to  receive  either  7.5  mg  ephedrine  or  50  
µg  phenylephrine  in  response  to  a  20%  decrease  from  baseline  mean  arterial  pressure  
(MAP),  if  this  is  associated  with  an  absolute  value  of  the  MAP  of  less  than  110  mmHg  
(target  value).    Should  the  MAP  not  be  restored  to  the  target  value  within  60  – 90  
seconds,  7.5-­15  mg  ephedrine  or  50-­100  µg  phenylephrine  will  be  given.    If  the  target  is  
not  achieved  after  a  total  of  either  45  mg  of  ephedrine  or  300  µg  of  phenylephrine,  the  
alternative  vasopressor  may  be  used.    Should  MAP  at  any  point  decrease  to  more  than  
30%  below  baseline,  15  mg  ephedrine  or  100  µg  phenylephrine  may  be  given.    If  HR  
decreases  to  less  than  55  beats  per  minute  in  association  with  hypotension  (MAP  
decrease  by  30%  from  baseline),  ephedrine  10  mg  will  be  administered,  followed  by  
atropine  0.25-­0.5  mg  if  bradycardia  persists.    No  patient  will  receive  more  than  50  mg  
ephedrine,  since  this  will  be  interpreted  as  tachyphylaxis.    Syringes  will  be  pre-­prepared  
by  an  investigator  not  involved  with  the  performance  of  the  anaesthesia,  so  that  the  
anaesthetist  will  be  blinded  as  to  the  vasopressor  given.    Randomisation  will  be  
performed  at  the  time  of  requirement  of  a  vasopressor.    Blocked  randomisation  will  be  
used  (randomised  block  sizes  of  4,  6  or  8  using  nquery  Advisor  Version  6,  Statistical  
Solutions,  Cork,  Ireland).    Sealed  envelopes  will  be  prepared  by  the  statistician.    
Twenty  seconds  after  delivery,  oxytocin  3.0  IU  in  3  mL  saline,  will  be  administered  over  a  
period  of  60  seconds.      
Umbilical  arterial  and  venous  blood  samples  will  be  collected  from  a  segment  of  double-­
clamped  umbilical  cord  shortly  after  delivery  and  arterial  and  venous  blood  gas  
parameters  will  be  determined.      
After  delivery,  phenylephrine  50  -­100  µg  or  ephedrine  7.5  – 15  mg  will  be  administered  in  
boluses  to  maintain  MAP  above  90  mmHg.      
Clinically  relevant  time  intervals  will  be  recorded:  
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a)                   Time  from  arrival  in  theatre  until  induction  of  anaesthesia  
b)     Time  to  T4  sensory  block  level  
c)     Induction  to  skin  incision  time  
d)     Induction  to  uterine  incision  time    
e)     Uterine  incision  to  delivery  time    
f)     Skin  incision  to  closure  time  
g)     Decision  – to  -­  delivery  time  
  
All  maternal  medication  received  in  the  24  hours  prior  to  anaesthesia  will  be  carefully  
noted.    Severity  of  disease  (as  assessed  by  the  degree  of  hypertension  and  the  
requirement  for  vasodilator  and/or  seizure  prophylaxis  therapy,  and  degree  of  
proteinuria)  and  presence  or  absence  of  labour  will  also  be  recorded.    Maternal  side-­
effects,  in  particular  nausea  and  vomiting,  will  be  noted.      
Neonatal  outcome  will  be  assessed  by  a  paediatrician  dedicated  to  the  study,  and  
blinded  to  the  method  of  anaesthesia.    Assessment  criteria  will  be  as  follows:    
The  primary  outcome  variable  will  be  umbilical  arterial  base  deficit.    Secondary  outcomes  
will  be  umbilical  arterial  and  venous  pH  and  lactate  level,  venous  base  deficit,  and  Apgar  
scores  at  1  and  5  minutes.    Umbilical  cord  blood  gas  values,  and  other  relevant  
anaesthesia  data  from  patients  not  requiring  vasopressor,  and  for  the  entire  study  cohort,  
will  also  be  collected,  so  that  the  study  also  will  also  serve  as  an  audit  of  practice.    A  
maternal  arterial  blood  gas  specimen  will  be  obtained  immediately  after  delivery.    The  
number  of  fetuses  with  pH  <  7.2  will  be  recorded,  as  well  as  those  with  an  umbilical  
arterial  base  deficit  >10  mmol·L-­1.    At  birth,  the  neonatal  weight,  gender,  gestational  age,  
one  and  five  minute  Apgar  score,  and  degree  of  resuscitation  (face  mask  ventilation,  
intubation  and  ventilation,  cardiopulmonary  resuscitation)  will  also  be  recorded.    In  
addition,  the  number  of  neonates  who  develop  high-­grade  intraventricular  haemorrhage  
or  hypoxic  ischaemic  encephalopathy  will  be  recorded.  
Statistical  analysis:  
The  primary  outcome  variable  will  be  the  fetal  base  deficit.    Sample  size  was  calculated  
as  follows:    A  previous  study  performed  at  our  institution  reported  an  umbilical  arterial  
base  deficit  of  8.7  ±  4.0  mEq/L  during  spinal  anaesthesia  in  patients  with  severe  
preeclampsia  and  a  non-­reassuring  fetal  heart  trace.    In  this  study,  ephedrine  was  used  
as  the  vasopressor.9    A  between  group  difference  of  3  mEq/L  was  hypothesised  as  
clinically  relevant  for  the  current  study.    Assuming  a  base  deficit  of  5.7  ±  3  mEq/L  in  the  
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comparator  group  (phenylephrine),  31  patients  would  be  required  in  each  group  for  90%  
power  to  detect  this  difference.    Therefore  32  patients  will  be  included  in  each  group.    
The  null  hypothesis  is  that  the  vasopressor  used  will  make  no  difference  to  neonatal  
umbilical  arterial  base  deficit  in  patients  with  severe  preeclampsia.    It  is  estimated  from  a  
previous  study  and  from  our  clinical  experience,  that  40%  of  patients  will  require  a  
vasopressor  pre-­delivery.    Hence  160  patients  will  be  recruited.        The  2  sample  t-­test  will  
be  used  for  the  statistical  comparison  of  the  two  randomised  groups  with  respect  to  the  
primary  outcome  and  other  continuous  variables  and  the  mean  difference  and  95%  
confidence  intervals  will  be  estimated.    For  categorical  outcomes,  Fisher’s  exact  test  will  
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PART  B:  LITERATURE  REVIEW  
  
1.   Objectives    
The  aim  of  the  information  presented  below  is  to  present  a  narrative  review  of  the  currently  
available  literature  regarding  the  use  of  ephedrine  and  phenylephrine  in  the  prevention  and  
treatment  of  spinal  hypotension.    The  information  as  regards  both  elective  and  emergency  
caesarean  deliveries  will  be  presented.    Specific  focus  will  be  on  the  fetal  effects  as  the  primary  
outcome  of  the  study  will  be  the  effects  of  the  two  agents  on  neonatal  base  excess.    This  review  
will  include  a  discussion  on  the  haemodynamic  effects  of  spinal  anaesthesia  for  caesarean  
section  as  well  as  the  pharmacodynamics  of  ephedrine  and  phenylephrine.    Reference  will  be  
made  to  the  definition  and  the  pathogenesis  of  preeclampsia  and  studies  regarding  spinal  
anaesthesia  in  severe  preeclampsia  and  the  use  of  vasopressors  will  be  reviewed.   
2.  Literature  Search  Strategy   
The  full  text  of  relevant  publications  was  obtained  online,  from  the  University  of  Cape  Town  
Health  Science  Library  search  facility.    Literature  published  between  the  years  1960  and  2016  
was  included.    In  total  47  relevant  papers  were  identified.    Literature  not  published  in  the  English  
language  was  excluded.   
3.  Quality  criteria   
The  keywords  used  for  the  search,  included  each  of  the  following,  in  various  combinations:  
phenylephrine,  ephedrine,  spinal  anaesthesia,  caesarean  delivery,  hypotension,  neonatal  blood  
gas,  preeclampsia,  acidosis,  emergency,  urgent.    Using  reference  lists,  further  appropriate  
papers  were  identified.   
4.  Summary  of  the  literature  
  4.1.  Introduction  
Spinal  anaesthesia  has  become  the  preferred  method  of  anaesthesia  for  caesarean  delivery  
(CD).    In  comparison  to  general  anaesthesia,  it  is  perceived  as  being  safer  as  it  avoids  potential  
difficulties  with  airway  manipulation.    Spinal  anaesthesia  has  also  been  shown  to  be  safe  and  
effective  in  patients  with  preeclampsia,  many  of  whom  have  the  greatest  risk  factors  for  
undergoing  general  anaesthesia.1    However,  spinal  anaesthesia  is  not  without  its  own  hazards.    
The  most  common  side  effect  is  hypotension  with  its  attendant  morbidity  for  both  mother  and  
fetus.    The  best  methods  of  treating  and  preventing  spinal  hypotension  have  been  a  subject  of  
investigation  and  debate  for  decades.    Vasoactive  drugs  are  an  essential  component  of  this.    
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The  majority  of  studies  have  centred  around  the  two  most  commonly  used  drugs:  ephedrine  and  
phenylephrine.    Traditionally,  ephedrine  was  advocated  as  the  treatment  of  choice  based  on  
animal  studies  in  pregnant  ewes  that  demonstrated  superior  maintenance  of  uterine  blood  flow  
and  placental  perfusion.2    However,  cumulative  evidence  over  the  past  two  decades  has  shown  
that  phenylephrine  is  not  only  more  efficacious  in  preventing  and  treating  spinal-­induced  
hypotension,  it  is  also  associated  with  a  lower  incidence  of  neonatal  acidosis.20,21,23-­25,29    The  
majority  of  this  evidence  is  from  studies  performed  in  healthy  patients  undergoing  elective  CD.    
There  is  less  evidence  to  support  one  vasopressor  above  the  other  in  regards  to  managing  
spinal  hypotension  in  cases  of  actual  or  possible  fetal  compromise  and/or  utero-­placental  
insufficiency.    Umbilical  cord  pH  has  been  shown  to  have  a  substantial  association  with  neonatal  
mortality  and  morbidity  with  a  four  times  increase  in  mortality  if  the  pH  is  <7.2.3    Thus,  it  is  of  
utmost  importance  to  endeavour  to  avoid  a  deterioration  in  neonatal  condition  though  prompt  
and  physiologically  appropriate  treatment  of  hypotension  with  agents  that  are  likely  to  maintain  
the  optimal  balance  between  fetal  oxygen  supply  and  demand.    This  is  of  particular  significance  
in  neonates  with  fetal  compromise,  especially  those  born  to  mothers  diagnosed  with  severe  
preeclampsia  who  are  likely  to  have  pre-­existing  utero-­placental  insufficiency.    
    4.2    Spinal  hypotension  
Hypotension  during  spinal  anaesthesia  for  CD  is  multifactorial.    It  may  be  compounded  by  
relative  or  absolute  hypovolaemia,  aorto-­caval  compression,  or  underlying  maternal  cardiac  
disease.    However,  it  is  mainly  the  consequence  of  sympathectomy-­induced  vasodilatation  
predominately  affecting  the  arterial  circulation.  
The  pathophysiology  of  this  sympathectomy  has  been  elucidated.    Studies  utilising  minimally  
invasive  cardiac  output  monitoring  have  shown  that  neuraxial  blockade  typically  results  in  a  
decrease  in  systemic  vascular  resistance  (SVR)  with  a  partial  compensatory  increase  in  cardiac  
output  (CO)  brought  about  by  increases  in  heart  rate  (HR)  and  stroke  volume  (SV).4,5  
Any  strategy  to  counteract  spinal  hypotension  and  optimise  fetal  condition  should  take  into  
account  three  factors,  namely:  reversing  the  above  mentioned  pathophysiological  changes,  
optimising  utero-­placental  blood  flow,  and  preventing  unfavourable  direct  fetal  effects.  
Most  patients  undergoing  elective  CD  will  require  a  vasopressor  to  achieve  this.    The  
vasopressor  should  be  chosen  based  on  maternal  and  fetal  side  effects,  maternal  
haemodynamic  effects  and  efficacy  and  titratability  of  the  agent.  
The  two  vasopressors  predominantly  in  use  in  clinical  practice  are  ephedrine  and  phenylephrine.  
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  4.3    Vasopressors:  
    4.3.a    Ephedrine  
Ephedrine  is  a  direct  acting  β  receptor  agonist,  with  indirect  α  and  β  effects  as  a  result  of  the  
stimulation  of  noradrenaline  release  from  sympathetic  nerve  terminals.6    The  end  effect  of  
ephedrine  administration  is  an  increase  in  HR,  CO  and  mean  arterial  pressure  (MAP).    The  
perceived  advantage  of  ephedrine  for  the  treatment  and  prophylaxis  of  spinal  hypotension  came  
about  largely  as  a  result  of  a  study  in  pregnant  ewes.2    In  this  study,  use  of  pure  α  agonists  was  
shown  to  cause  uterine  artery  vasoconstriction  and  a  decrease  in  placental  blood  flow.    With  
ephedrine  administration,  uterine  blood  flow  was  unchanged.    There  was  however  no  significant  
change  in  terms  of  fetal  blood  gas  and  acid-­base  variables.  
However,  it  has  been  noted  that  various  differences  in  human  and  sheep  anatomy  and  
physiology  make  this  finding  less  relevant  in  clinical  practice.7    The  human  placenta  is  a  low  
pressure  haemochorial  system  with  a  relatively  thin  barrier  to  diffusion  between  the  maternal  and  
fetal  side.    During  pregnancy,  the  uterine  arteries  are  maximally  dilated  as  a  result  of  increased  
nitric  oxide  and  prostacyclin  production  as  well  as  a  reduced  sensitivity  to  the  effects  of  
circulating  catecholamines.    The  spiral  arteries  supplying  the  intervillous  space  are  remodelled  
by  invading  fetal  cytotrophoblasts,  becoming  significantly  enlarged  and  losing  the  ability  to  
vasoconstrict.    Blood  flow  is  therefore  pressure  dependent  and  thus,  the  concerns  regarding  α  
agonist  induced  vasoconstriction  are  less  relevant  than  ensuring  preservation  of  systemic  
pressure.8    
In  contrast,  the  sheep  placenta  is  a  high  pressure  epitheliochorial  system  that  does  not  undergo  
the  same  remodelling.    Denervation  of  the  uterine  artery  also  occurs  but  is  accompanied  by  an  
increase  in  sensitivity  of  the  postsynaptic  α  adrenergic  receptors.    Thus  in  the  sheep  model  
catecholamines  may  cause  more  uterine  than  systemic  effects.7    
In  addition,  most  animal  studies  have  been  performed  under  varying  circumstances  that  make  
their  results  difficult  to  compare  to  humans  undergoing  neuraxial  anaesthesia.    For  example,  the  
ewes  in  these  studies  either  received  no  anaesthesia,  general  anaesthesia  or  a  combination  of  
the  two.    Only  one  study  used  spinal  anaesthesia  alone.    The  doses  of  vasopressor  used  were  
also  greater  than  those  used  in  clinical  practice.9  
Human  studies  are  available  comparing  the  effects  of  ephedrine  vs.  phenylephrine  and  other  α  
agonists  on  the  uteroplacental  circulation  using  the  doppler  derived  pulsatility  index  as  a  
measure  of  vascular  resistance.    Results  are  conflicting.    Alahuhta  et  al.  compared  ephedrine  
and  phenylephrine  and  reported  that  in  patients  receiving  phenylephrine,  mean  maternal  uterine  
and  placental  arcuate  artery  pulsatility  index  values  were  increased  compared  to  the  baseline.  
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This  did  not  occur  in  patients  receiving  ephedrine.10    In  contrast,  Ngan  Kee  et  al  demonstrated  in  
a  2001  study  that  there  was  no  significant  difference  in  uterine  artery  pulsatility  index  between  
patients  who  received  prophylactic  ephedrine  or  metaraminol  infusions  (an  α  agonist  with  similar  
effects  to  phenylephrine).11  
Ephedrine  demonstrates  low  efficacy  for  restoration  of  blood  pressure.12    Ephedrine  has  a  
relatively  slow  onset  to  peak  effect  compared  to  phenylephrine  (median  78  seconds  [sec]  vs.  27  
sec  using  beat-­by-­beat  finger  arterial  pressure,  p=0.006).13    A  2009  study  of  haemodynamics  
using  pulse  wave  analysis  demonstrated  that  it  took  approximately  40  sec  for  phenylephrine  to  
restore  MAP  following  spinal  anaesthesia,  compared  to  90  sec  for  ephedrine.5    
Ephedrine  has  also  has  been  found  to  be  less  effective  for  prevention  of  nausea  and  vomiting  
during  spinal  anaesthesia  for  CD.21-­24,26    It  has  the  sometimes  unwanted  side  effect  of  
tachycardia.  In  addition,  continued  use  results  in  tachyphylaxis  to  the  indirect  actions.14  
    4.3.b    Phenylephrine  
Phenylephrine  is  a  short  acting,  rapid  onset,  potent,  direct  acting  α  agonist  synthetically  derived  
from  adrenaline.15  
As  already  stated,  the  typical  response  to  spinal  anaesthesia  for  CD,  is  a  reduction  in  SVR  with  
a  partial  compensatory  increase  in  HR  and  CO.5  
In  most  cases,  the  spinal-­induced  decrease  in  SVR  may  be  effectively  prevented  or  treated  by  
the  use  of  either  low-­dose  boluses  or  a  low-­dose  infusion  of  phenylephrine  thereby  restoring  
baseline  blood  pressure,  HR  and  CO.    Dyer  et  al  suggest  that  HR  should  be  taken  as  a  
surrogate  of  CO  and  to  titrate  phenylephrine  to  restore  CO  to  baseline  in  healthy  elective  
patients.5    However,  doses  that  cause  an  increase  in  MAP  above  baseline  with  sinus  
bradycardia  may  be  associated  with  a  decrease  in  CO  and  should  be  avoided.    It  is  postulated  
that  significant  reductions  in  CO  may  have  the  potential  to  harm  a  compromised  fetus  with  little  
reserve.16,17  
Studies  of  umbilical  arterial  gases  from  neonates  whose  mothers  received  high  dose  
phenylephrine  infusions  to  maintain  MAP  have  shown  that  pH  and  base  excess  (BE)  values  are  
well  preserved,  even  when  given  in  high  doses.17    This  observation  suggests  that  despite  the  
potential  for  uterine  artery  vasoconstriction  observed  in  animal  studies,  phenylephrine  preserves  
blood  flow  by  an  increase  in  uterine  perfusion  pressure.  
Phenylephrine  has  however  been  shown  to  decrease  umbilical  venous  oxygen  partial  pressure  
(UVPO2)  which  could  suggest  a  reduction  in  flow  due  to  vasoconstriction.22,24    Again,  this  has  not  
been  correlated  with  a  worsening  of  fetal  acid  base  status  or  Apgar  scores  possibly  because  of  
the  existence  of  significant  placental  reserve  for  oxygen  delivery.7    Animal  studies  have  shown  
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that  uterine  artery  blood  flow  is  higher  than  that  required  by  fetal  demand  and  is  thus  able  to  
provide  a  margin  of  safety.18  
In  summary,  phenylephrine  has  been  shown  to  be  effective  in  restoring  vascular  tone  to  normal  
during  spinal  anaesthesia  for  CD  without  an  adverse  effect  on  fetal  oxygen  supply  demand  
balance.19  
4.4    Phenylephrine  vs.  Ephedrine  for  the  treatment  and  prophylaxis  of  spinal-­
induced  hypotension:  
    4.4.a    Elective  cases  
A  systematic  review  of  ephedrine  vs.  phenylephrine  for  the  management  of  hypotension  during  
spinal  anaesthesia  for  CD  was  published  by  Lee  et  al  in  2002.20    This  identified  7  randomised  
controlled  trials  over  the  period  1966  to  2001.    Neonates  whose  mothers  were  given  
phenylephrine  had  higher  umbilical  pH  values  that  those  whose  mothers  were  treated  with  
ephedrine.    However,  there  was  no  difference  in  the  incidence  of  a  pH  <7,2  (seen  as  true  fetal  
acidosis)  and  no  difference  in  Apgar  scores  less  than  7  at  1  and  5  minute  intervals.    The  
difference  in  the  pH  was  not  shown  to  be  clinically  significant.    They  concluded  by  challenging  
the  traditional  view  that  preferred  the  use  of  ephedrine  over  phenylephrine.    Of  note,  all  the  
patients  in  the  included  studies  were  reported  to  be  healthy  and  non-­labouring.  
Multiple  trials  in  healthy,  ASA  1-­2  women  undergoing  elective  CD  followed  on  from  this  in  an  
attempt  to  better  define  the  effect  of  the  two  vasopressors  on  fetal  outcome  (with  UApH  and  BE  
as  a  proxy).  
Cooper  et  al  in  a  RDBT  in  2002  demonstrated  a  significantly  lower  UApH  and  BE  with  ephedrine  
as  well  as  an  increased  risk  of  an  UApH  <7,2.21    Patients  were  recruited  to  receive  either  a  
phenylephrine  infusion,  an  ephedrine  infusion  or  a  combination  of  the  two  to  maintain  systolic  
blood  pressure  (SBP)  at  baseline.    Only  1  of  the  48  neonates  in  the  phenylephrine  group,  and  1  
of  the  47  in  the  combination  group  were  acidotic,  compared  with  10  of  48  in  the  ephedrine  group.    
Of  note  in  this  study,  the  patients  were  likely  to  have  received  relatively  large  doses  of  ephedrine  
as  infusions  were  used  (mean  dose  1,5  mg/min)  and  the  spinal  to  delivery  interval  ranged  
between  24-­30  minutes.    The  cord  blood  gases  in  the  ephedrine  arm  were  also  noted  to  have  a  
greater  umbilical  arterio-­venous  partial  pressure  of  carbon  dioxide  difference  [(A-­V)  PCO2]  which  
correlated  with  increasing  ephedrine  dose.    The  authors  postulated  that  the  mechanism  for  the  
decrease  in  pH  may  be  an  increase  in  fetal  metabolism  as  a  result  of  a  direct  effect  of  ephedrine.    
There  was  however  no  difference  in  Apgar  scores,  neonatal  outcome  or  admission  to  the  
neonatal  unit.    However,  the  authors  did  raise  concern  that  in  compromised  fetus’s  the  increase  
in  metabolism  may  be  detrimental  to  those  at  the  limit  of  their  reserve.  
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The  mechanism  of  acidosis  was  further  elucidated  in  a  2009  study.22    A  comparison  was  made  
of  various  biochemical  indices  between  neonates  whose  mothers  were  exposed  to  either  
phenylephrine  or  ephedrine  infusions.    These  included  UA  pH,  BE,  PCO2,  UV  PO2,UA/UV  
plasma  lactate  difference,  glucose,  adrenaline  and  noradrenaline  concentrations.      
In  the  ephedrine  group,  UA  and  UV  pH  and  BE  were  lower;;  and  in  addition,  concentrations  of  
lactate,  glucose,  adrenaline  and  noradrenaline  were  greater.  Umbilical  arterial  PCO2  and  UV  
PO2  were  also  greater  in  the  ephedrine  group.    Placental  transfer  was  significantly  greater  for  
ephedrine  and  it  appeared  to  undergo  less  metabolism  or  redistribution  in  the  fetus  than  
phenylephrine  (median  umbilical  venous/maternal  arterial  concentration  ratio  1.13  versus  0.17).  
This  supported  the  hypothesis  that  the  effects  of  ephedrine  on  acid  base  were  due  to  transfer  
across  the  placenta  and  direct  stimulation  of  fetal  β  receptors  resulting  in  an  increase  in  fetal  
metabolism.  
Further  randomised  controlled  trials  in  elective  CD  continued  to  show  significantly  decreased  
UApH  and  UABE  values  in  neonates  exposed  to  ephedrine  whether  as  a  continuous  infusion  or  
as  boluses.5,22-­26  
The  total  dose  of  ephedrine  given  correlates  with  worsening  fetal  acid-­base  profile.  24,25      
However  even  at  lower  doses,  there  is  still  a  trend  towards  a  lower  fetal  pH.8      It  may  be  possible  
that  some  fetuses  are  more  at  risk  of  developing  a  clinically  significant  acidosis  in  response  to  
ephedrine  exposure  based  on  their  genetic  profile.    In  a  randomised  study  of  Chinese  women  
receiving  either  ephedrine  or  phenylephrine  infusions,  neonatal  birth  weight  and  genotype  but  
not  ephedrine  dose  were  found  to  predict  neonatal  acidosis.    This  was  dependent  on  the  β2  
adrenoreceptor  haplotype.  Neonates  that  were  homozygous  for  Arg16  were  protected  from  
developing  an  acidosis  when  their  mothers  were  treated  with  ephedrine.27    Therefore  even  small  
doses  of  ephedrine  may  result  in  significant  acidosis  in  susceptible  neonates  despite  the  fact  
that  the  average  UApH  and  BE  in  a  given  cohort  may  be  unaffected.8  
A  recent  systematic  review  and  cumulative  meta-­analysis  in  2012  clearly  showed  a  decreased  
risk  for  fetal  acidosis  with  the  use  of  phenylephrine.    In  fact,  the  relative  risk  of  true  fetal  acidosis  
(pH  <7,2)  was  5,29  for  ephedrine  vs.  phenylephrine  (p=0,006).29  
    4.4.b    Emergency  cases  
It  is  important  to  consider  the  adverse  effects  that  vasopressor  treatment  could  have  on  a  
potentially  compromised  fetus.    A  fetus  with  an  already  impaired  utero-­placental  circulation  may  
not  be  able  to  compensate  for  any  further  reduction  in  flow  due  to  vasoconstriction  or  decreased  
CO.    Equally,  it  may  not  be  able  to  cope  with  the  increase  in  oxygen  demand  as  a  result  of  
ephedrine  stimulated  increases  in  metabolism.  
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In  this  situation,  animal  studies  again  have  suggested  a  preference  for  ephedrine.    Erkinaro  et  al  
studied  the  effects  of  phenylephrine  and  ephedrine  for  the  treatment  of  hypotension  in  a  sheep  
model  of  increased  vascular  resistance.30    These  sheep  were  rendered  hypoxic  and  
hypotensive.    Both  ephedrine  and  phenylephrine  were  able  to  restore  haemodynamics.    
However,  ephedrine  did  so  without  any  deterioration  in  fetal  lactate  concentration  while  the  
phenylephrine  group  demonstrated  a  continued  deterioration  in  lactate  values.      
This  has  not  been  replicated  in  the  few  human  studies  in  the  literature.    
Ngan  Kee  et  al,  in  2008,  conducted  a  randomised  comparison  of  bolus  phenylephrine  and  
ephedrine  for  treating  hypotension  under  spinal  anaesthesia  for  non-­elective  CD.31    They  found  
that  UA  and  UV  pH  and  BE  were  similar.    UA  and  UV  lactate  were  higher  in  the  ephedrine  
group.    UV  and  UA  p02  was  lower  in  the  phenylephrine  group  but  oxygen  content  was  similar.    
There  was  no  difference  in  Apgar  scores  or  clinical  outcome.    They  concluded  that  both  
vasopressors  were  suitable  for  use  in  non-­elective  CD.  
Importantly,  the  patients  enrolled  were  ASA  status  1/2  with  term  pregnancies.    No  patients  
enrolled  were  diagnosed  with  preeclampsia.    The  median  dose  of  ephedrine  received  was  10  mg  
(IQR  10-­30  mg)  which  was  small  in  comparison  to  doses  used  in  previous  studies  in  elective  
cases.  
Of  204  patients;;  148  patients  received  a  vasopressor  and,  of  those  30  were  deemed  to  have  
fetal  compromise.    Sub-­analysis  of  this  group  showed  that  UAPO2  was  lower  in  the  
phenylephrine  group  but  all  other  gas  parameters  and  lactate  values  were  similar.    The  authors  
postulated  that  this  may  reflect  vasoconstriction,  reduced  uteroplacental  blood  flow  and  
increased  fetal  oxygen  extraction.      
Cooper  et  al  published  a  retrospective  study  of  the  association  between  choice  of  vasopressor  
and  fetal  pH  during  high  risk  CD  (defined  as  CD  for  “non-­reassuring  fetal  heart  rate  tracing  
(NRFHRT),  dystocia,  pregnancy-­induced  hypertension,  growth  restriction,  antepartum  
haemorrhage,  prolonged  rupture  of  membranes,  or  cord  prolapse”).32  
UApH  was  similar  whether  ephedrine  or  phenylephrine  was  used.    Using  multiple  regression  
analysis,  they  identified  that  the  only  variable  associated  with  a  low  pH  was  a  NRFHRT.    They  
concluded  that  the  likely  reason  for  the  similar  pH  between  groups  was  that  a  lower  total  dose  of  
ephedrine  (mean  12  mg  [IQR  6-­8  mg])  had  been  given  in  comparison  to  previous  studies  in  
elective  cases.      
A  more  recent  study  compared  ephedrine  8  mg  and  phenylephrine  100  μg  in  a  group  of  healthy  
patients  undergoing  emergency  CD  for  fetal  compromise.    They  found  no  between-­group  
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differences  in  UA  and  UV  pH,  PO2,  PCO2,  BE,  or  the  incidence  of  fetal  acidosis.    Apgar  scores  
and  early  fetal  outcome  were  also  comparable.33  
There  is  a  lack  of  studies  addressing  the  question  of  whether  phenylephrine  or  ephedrine  is  
associated  with  an  improved  acid/base  profile  when  used  for  spinal-­induced  hypotension  in  
patients  with  severe  preeclampsia  and  fetal  distress.  
    4.5    Preeclampsia  
Preeclampsia  is  a  unique  maternal  multi-­systemic  disease  that  manifests  after  20  weeks  of  
gestation.    The  diagnostic  criteria  are  as  follows:  
1.)  A  blood  pressure  greater  than  or  equal  to  140  mmHg  systolic  or  greater  than  or  equal  to  
90  mmHg  diastolic  on  two  occasions  at  least  4  hours  apart  in  a  woman  with  a  previously  
normal  blood  pressure.  
2.)  Proteinuria  greater  than  or  equal  to  300  mg  per  24  hours  or  a  protein/creatinine  ratio  
greater  than  or  equal  to  0,3  (or  dipstick  of  1+  or  greater  if  other  quantitative  methods  are  not  
available).34  
In  the  absence  of  proteinuria,  preeclampsia  is  diagnosed  when  there  is  new  onset  
hypertension  with  any  of  the  following:  thrombocytopaenia,  renal  insufficiency,  impaired  liver  
function,  pulmonary  oedema,  cerebral  or  visual  symptoms.    The  presence  of  these  features  
is  a  marker  of  severe  disease.  
The  disease  may  otherwise  be  considered  severe  when  there  is  a  SBP  of  160  mmHg  or  
higher,  or  diastolic  blood  pressure  (DBP)  of  110  mmHg  or  higher  on  two  occasions  at  least  4  
hours  apart  while  the  patient  is  on  bed  rest  (unless  antihypertensive  therapy  is  initiated  
before  this  time).  
The  hypertension  of  preeclampsia  is  characterised  by  peripheral  vasoconstriction  and  
reduced  arterial  compliance.35  Patients  also  develop  cardiac  dysfunction,  most  commonly  
diastolic  dysfunction.  36,37    Inotropy  is  often  preserved  or  even  increased.    However,  cases  of  
severe  left  ventricular  dysfunction  and  global  biventricular  systolic  dysfunction  also  occur  
(Melchiorre,  2012).37  
There  is  a  distinction  between  early  onset  (less  than  34  weeks  gestation)  and  late  onset  
disease  (greater  than  or  equal  to  34  weeks  gestation).    Women  with  early  onset  disease  are  
more  likely  to  develop  severe  pre-­eclampsia,  HELLP  syndrome  and  eclampsia  than  those  
with  late  onset  disease  (adjusted  odds  ratio  [aOR]  5,8).    In  addition,  fetal  death  is  more  likely  
with  an  aOR  of  1,3.38    
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Early  onset  preeclampsia  is  associated  with  a  higher  SVR,  lower  CO  and  worse  myocardial  
impairment  -­  systolic  and  diastolic.39,40    Neonates  born  to  mothers  with  preeclampsia  may  
suffer  intrauterine  growth  restriction  (IUGR),  oligohydramnios  or  problems  related  to  
prematurity  as  a  result  of  the  necessity  for  preterm  delivery.    Interestingly,  they  are  less  likely  
to  demise  in  the  neonatal  period  compared  to  babies  born  at  the  same  gestational  age  to  
woman  without  preeclampsia.38  
The  pathogenesis  of  preeclampsia  is  complex  and  still  a  subject  of  ongoing  research.    There  
is  evidence  that  the  end  result  of  the  pathophysiological  process  is  damage  to  the  vascular  
endothelium  including  the  endothelium  of  the  glomerular  capillaries  and  the  choroid  plexus.    
It  is  thus  a  multi-­system  disease  affecting  the  renal,  hepatic,  neurologic,  cardiac,  pulmonary  
and  uteroplacental  systems.    
The  placenta  maintains  a  key  role  in  the  pathogenesis  with  abnormalities  of  placental  
development  preceding  any  detectable  maternal  features.35  
Normal  placentation  involves  invasion  of  the  uterine  wall  and  decidual  vessels  by  the  
embryonal  cytotrophoblasts.    These  cells  undergo  cellular  mimicry,  adopting  an  endothelial  
phenotype  and  inducing  maternal  decidual  vessel  remodelling  to  form  high  capacitance,  low  
resistance  vessels.    This  process  is  incomplete  in  preeclampsia.    The  cytotrophoblasts  do  
not  invade  beyond  the  superficial  layers  of  the  decidua  and  remodelling  does  not  take  place;;  
resulting  in  constricted,  high  resistance  vessels.  
Abnormal  uterine  artery  Doppler  waveforms  suggestive  of  decreased  placental  perfusion  
have  been  shown  to  herald  the  development  of  preeclampsia  and  placental  hypoxia  is  
implicated  in  the  development  of  the  disease  in  the  mother.41  
There  are  multiple  homeostatic  mechanisms  at  work  to  maintain  a  healthy  endothelium.    
Disruption  to  the  normal  balance  between  anti  and  pro-­angiogenic  factors  in  pregnancy  may  
be  the  final  common  pathway  to  the  development  of  disease.    Recently  identified  circulating  
anti-­angiogenic  proteins  (specifically  soluble  fms-­like  tyrosine  kinase  [sFlt-­1]  and  soluble  
endoglin  [sEng])  released  from  the  abnormal  placenta  have  been  implicated  in  this  
disruption.    There  is  an  imbalance  between  these  and  the  effects  of  pro-­angiogenic  factors  
(VEGF,  PlGF,  and  TGF-­b).    It  is  this  imbalance  which  results  in  the  features  of  the  maternal  
disease  and  may  result  in  an  increased  risk  of  cardiovascular  disease  in  later  life.35    
    4.6    Severe  Preeclampsia  and  Spinal  Anaesthesia:  
Patients  with  severe  preeclampsia  have  less  frequent  and  less  severe  hypotension  in  
response  to  spinal  anaesthesia.38,42    As  a  result,  they  often  require  reduced  doses  of  
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vasopressors.    However,  at  the  same  time  they  are  vulnerable  to  a  reduction  in  
uteroplacental  perfusion.  
There  have  been  no  prospective  studies  published  to  date  specifically  examining  the  effects  
of  phenylephrine  vs.  ephedrine  on  neonatal  outcome  when  used  to  counteract  spinal  
hypotension  in  mothers  with  severe  preeclampsia  and  fetal  distress.    The  majority  of  studies  
regarding  spinal  anaesthesia  for  severe  preeclampsia  in  the  literature  have  compared  either  
spinal  with  epidural  anaesthesia  or  spinal  with  general  anaesthesia.43-­45.    All  these  studies  
have  used  ephedrine  to  counteract  predetermined  levels  of  hypotension.    Visalyaputra  et  al.  
found  that  patients  randomised  to  receive  spinal  anaesthesia  had  double  the  incidence  of  
significant  hypotension  than  their  epidural  counterparts.    However,  the  duration  of  
hypotension  was  short.    The  spinal  anaesthesia  cohort  received  significantly  more  ephedrine  
(0-­18  mg  [0]  vs  0-­36  mg  [6])  but  there  was  no  difference  in  neonatal  acid  base  indices  or  in  
Apgar  scores.43    
A  study  published  in  2003  compared  general  anaesthesia  vs  spinal  for  CD  in  preeclamptic  
patients  with  a  NRFHRT.45    Neonates  born  to  mothers  randomised  to  spinal  anaesthesia  had  
significantly  higher  base  deficits  and  lower  pH  values  despite  similar  haemodynamics.    All  
patients  received  ephedrine  for  hypotension  but  significantly  more  was  required  in  the  spinal  
group  (13,7  mg  vs  2,7  mg  P=0.002).    However,  there  was  no  correlation  between  ephedrine  
use  and  neonatal  base  deficit  in  either  group  and,  there  was  no  correlation  between  
ephedrine  use  and  neonatal  base  deficit  in  the  spinal  group  overall  and  in  particular  in  the  
case  of  neonates  with  a  base  deficit  more  than  10  mmol/l.    Interestingly,  a  subgroup  analysis  
showed  a  significant  difference  in  base  deficit  only  when  maternal  DBP  was  greater  than  110  
mmHg.    However,  the  significance  is  unknown  as  the  study  was  not  powered  to  assess  this  
group  of  patients.  
In  severe  pre-­eclampsia  haemodynamic  goals  during  anaesthesia  are  to  optimise  maternal  
BP  and  CO  as  well  as  uteroplacental  perfusion.    Dyer  et  al.  investigated  the  haemodynamic  
changes  associated  with  spinal  anaesthesia  and  the  administration  of  phenylephrine  for  CD  
in  severe  pre-­eclampsia  with  the  use  of  beat  to  beat  cardiac  output  monitoring  (LiDCOPlus).  
46      When  MAP  decreased  to  less  than  20%  of  baseline,  SVR  was  also  shown  to  be  
significantly  below  baseline  but  CO  and  HR  did  not  differ.    The  administration  of  
phenylephrine  resulted  in  a  significant  increase  in  SVR  and  MAP.    Heart  rate  decreased  
significantly  but  SV  and  CO  did  not  change.    The  main  effect  of  spinal  anaesthesia  was  
concluded  to  be  a  modest  reduction  in  afterload.    Phenylephrine  administration  was  
associated  with  a  trend  towards  a  reduction  in  CO  but  the  mean  change  was  not  significant.    
No  observations  were  made  regarding  uteroplacental  perfusion  but  the  median  (range)  
UApH  was  7,28  (7,19-­7,31)  and  the  mean  (SD)  BD  was  -­3,1  (1,9)  mmol/l.    
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Ituk,  Cooter  and  Habib  undertook  a  retrospective  comparison  of  bolus  administered  ephedrine  
and  phenylephrine  for  the  treatment  of  spinal-­induced  hypotension  in  preeclamptic  patients  
undergoing  CD  in  their  institution  between  January  2005  and  July  2014.47    The  primary  outcome  
was  umbilical  arterial  pH.    One  hundred  and  forty  six  patients  were  included  in  the  analysis.    The  
results  showed  no  difference  in  pH  whether  ephedrine  or  phenylephrine  was  used  with  a  median  
pH  of  7,3  (IQR  7.20-­7.30)  in  both  groups  (P=0.41).    There  was  also  no  significant  difference  in  
base  excess,  1  min  and  5  min  Apgar  scores  or  in  the  number  of  neonates  with  an  UApH  <7.2.    
They  noted  in  their  discussion  that  the  majority  of  cases  were  classified  as  category  I/II  CDs  (in  
accordance  with  the  Royal  College  of  Obstetricians  and  Gynaecologists)  and  thus  the  urgent  
nature  of  the  case  likely  resulted  in  a  shorter  interval  between  induction  of  spinal  anaesthesia  
and  delivery.    In  comparison  to  most  of  the  previously  performed  elective  studies,  this  would  
have  resulted  in  less  vasopressor  being  required  pre-­delivery  and  specifically  less  fetal  exposure  
to  ephedrine.    
The  comparison  was  however  limited  by  its  retrospective  nature.    There  were  significant  
differences  between  the  two  groups  in  terms  of  patient  characteristics,  the  indications  for  CD  and  
the  doses  of  vasopressor  used.  
More  patients  in  the  phenylephrine  group  were  classified  with  severe  preeclampsia  (98.9%)  
compared  to  the  ephedrine  group  (82.5%)  (p=0.0004).    The  neonates  in  the  ephedrine  group  
had  a  lower  gestational  age  (32  weeks  vs.  36  weeks;;  p=0.002)  and  had  a  lower  birthweight  (1.8  
kg  vs.  2.6  kg;;  p=0.03).  
77%  of  deliveries  in  the  ephedrine  group  and  81%  in  the  phenylephrine  group  were  classified  as  
category  I  or  II  (P=0.59).    However,  in  the  breakdown  of  indications  for  delivery,  17.5%  of  the  
ephedrine  group  had  a  NRFHRT  compared  to  3.4%  of  the  phenylephrine  group.    Severe  
preeclampsia  alone  was  an  indication  in  49.1%  of  the  ephedrine  group  and  85.4%  in  the  
phenylephrine  (p<0.0004).    
Lastly,  the  median  dose  of  vasopressor  used  was  lower  in  the  ephedrine  than  the  phenylephrine  
groups.  
Multivariate  regression  analysis  showed  a  NRFHT  to  be  the  only  variable  associated  with  a  
significantly  lower  UApH.    
    4.7    Conclusion:  
Hypotension  in  response  to  spinal  anaesthesia  may  be  a  result  of  a  number  of  differing  
factors:  sympathetic  blockade,  aortocaval  compression,  underlying  intravascular  depletion  
and  possible  left  ventricle  dysfunction.    With  this  in  mind,  it  is  important  to  select  a  treatment  
(vasopressor)  that  is  physiologically  appropriate  to  the  derangements  within  the  index  
patient.  
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There  are  many  influences  on  the  neonatal  outcome  after  CD  in  patients  with  preeclampsia  
including  the  severity  of  disease,  the  degree  of  uteroplacental  insufficiency,  the  treatment  
received  and  the  anaesthesia  and  surgical  management.    In  the  context  of  these  many  
factors,  it  is  not  known  whether  the  treatment  of  spinal  induced  hypotension  with  
phenylephrine  or  ephedrine  has  any  impact  on  the  neonatal  outcome.    Studies  in  elective  
healthy  patients  have  clearly  shown  that  ephedrine  results  in  more  fetal  acidosis,  whereas  
studies  of  non-­elective  cases  have  found  no  difference.    This  would  be  the  first  randomised  
comparison  of  the  effect  on  acid  base  values  and  early  neonatal  outcome  of  the  use  of  
phenylephrine  vs.  ephedrine  for  spinal  hypotension  in  patients  with  severe  preeclampsia  and  
a  NRFHRT.  
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Background:  Studies  in  healthy  patients  undergoing  elective  caesarean  delivery  show  
that  ephedrine  used  for  spinal  hypotension  is  associated  with  increased  fetal  acidosis  
compared  with  phenylephrine.    This  has  not  been  investigated  prospectively  in  severe  
preeclampsia.  
Methods:  Patients  with  severe  preeclampsia  requiring  caesarean  delivery  for  a  non-­
reassuring  fetal  heart  tracing  were  randomised  to  receive  bolus  ephedrine  (7.5-­15  mg)  or  
phenylephrine  (50-­100  µg)  for  spinal  hypotension.    The  primary  outcome  was  umbilical  
arterial  base  deficit.    Secondary  outcomes  were  umbilical  arterial  (UA)  and  venous  (UV)  
pH  and  lactate  level,  venous  base  deficit,  and  Apgar  scores.  
Results:  A  total  of  133  women  were  included;;  64  required  vasopressor  treatment  and  
were  randomised  to  2  groups  of  32  with  similar  patient  characteristics.    Pre-­delivery  
blood  pressure  changes  were  similar  in  the  2  groups.    There  was  no  difference  in  mean  
[SD]  UA  base  deficit  (-­4.9  [3.7]  vs  -­6.0  [4.6]  mmol·L-­1  for  ephedrine  and  phenylephrine  
respectively;;  P  =  0.29).    Mean  [SD]  pH  (UA  and  UV)  and  lactate  levels  were  also  similar  
between  groups  (7.25  [0.08]  vs  7.22  [0.10],  7.28  [0.07]  vs  7.27  [0.10],  and  3.41  [2.18]  vs  
3.28  [2.44]  mmol·L-­1  respectively).    In  addition,  UV  PO2  was  higher  in  the  ephedrine  
group  (2.8  [0.7]  vs  2.4  [0.62])  kPa,  P  =  0.02).    There  was  no  difference  in  1-­  or  5-­minute  
Apgar  scores,  numbers  of  neonates  with  1-­minute  Apgar  scores  <  7  (10/32  [31%]  vs  
12/32  [38%]),  or  with  a  pH  <  7.2  (6/31  [19%]  vs  8/29  [28%]).      
Conclusions:  In  patients  with  severe  preeclampsia  and  fetal  compromise,  fetal  acid-­
base  status  is  independent  of  the  use  of  bolus  ephedrine  vs  phenylephrine  to  treat  spinal  
hypotension.  
  
Keywords:  ephedrine,  fetal  compromise,  phenylephrine,  preeclampsia,  spinal  
hypotension,  vasopressor  
  








   Introduction  
  
Spinal  hypotension  during  caesarean  delivery  remains  a  significant  clinical  challenge;;  
maternal  nausea  and  vomiting  and  fetal  compromise  may  result.    Ephedrine  and  
phenylephrine  are  commonly  used  to  prevent  and  treat  spinal  hypotension.    In  healthy  
patients  with  no  fetal  compromise,  ephedrine  is  associated  with  more  fetal  acidosis  than  
phenylephrine.1    The  clinical  significance  of  this  difference  is  likely  minimal  unless  large  
doses  are  administered.2    One  study  suggests  that  acidosis  may  arise  after  low  doses  of  
ephedrine  in  genetically  susceptible  individuals.3    There  is  limited  data  regarding  
vasopressor  use  in  mothers  with  a  compromised  fetus  or  placental  function.4-­7    In  these  
women  it  is  possible  that  the  unfavourable  oxygen  supply-­demand  ratio  caused  by  
ephedrine-­induced  increased  fetal  metabolic  rate  may  be  deleterious.      
  
In  women  with  preeclampsia,  spinal  anaesthesia  is  associated  with  less  hypotension  than  
in  healthy  patients.8    Typically,  it  causes  modest  afterload  reduction,  which  may  be  
beneficial.9    However,  clinically  significant  hypotension  may  occur  in  some  patients.    A  
retrospective  comparison  of  the  use  of  phenylephrine  and  ephedrine  during  spinal  
anaesthesia  for  caesarean  delivery  in  women  with  preeclampsia,  included  women  with  
both  maternal  and  fetal  indications  for  delivery.6    There  were  no  between-­group  
differences  in  umbilical  arterial  pH.6    The  aim  of  our  randomised  trial  was  to  compare  the  
use  of  bolus  ephedrine  and  phenylephrine  for  the  treatment  of  spinal  hypotension  in  
women  with  severe  preeclampsia  with  a  non-­reassuring  fetal  heart  tracing  undergoing  
caesarean  delivery.    The  primary  outcome  variable  was  the  umbilical  arterial  (UA)  base  
deficit.    Secondary  outcomes  were  umbilical  arterial  and  venous  (UV)  pH  and  lactate  
level,  venous  base  deficit,  and  Apgar  scores  at  1  and  5  minutes.    Overall  results  for  the  
entire  cohort  of  recruited  patients,  including  those  not  requiring  vasopressor  pre-­delivery,  
are  also  presented.  
                      Methods  
The  study  commenced  after  the  approval  of  the  Health  Science  Faculty  Human  
Research  Ethics  Committee  of  the  University  of  Cape  Town.    It  was  registered  with  the  
South  African  National  Clinical  Trial  Register  before  the  start  of  recruitment  (DOH  -­27-­
111-­3888),  and  performed  at  the  New  Groote  Schuur  Hospital  Maternity  Centre.    
Informed  written  consent  was  obtained  immediately  after  the  patient  was  scheduled  for  
caesarean  delivery.    Fetal  cardiotocography  was  interpreted  by  the  obstetricians,  
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according  to  the  guidelines  of  the  Royal  College  of  Obstetricians  and  Gynaecologists.10    
Patients  with  severe  preeclampsia  requiring  caesarean  delivery  for  a  non-­reassuring  fetal  
heart  tracing  were  recruited.  
Recent  recommendations  are  that  proteinuria  is  no  longer  an  absolute  requirement  for  
the  diagnosis  of  preeclampsia,  and  a  new  nomenclature,  “preeclampsia  with  severe  
features”,  has  been  advocated.11      At  the  time  of  initiation  of  the  present  study,  
preeclampsia  was  diagnosed  if  the  diastolic  blood  pressure  after  20  weeks’  gestational  
age  was  greater  than  or  equal  to  90  mmHg  on  two  separate  occasions  at  least  4  hours  
apart,  and  there  was  proteinuria  of  2+  on  urine  dipstix  in  two  clean  midstream  samples  
taken  at  least  4  hours  apart,  or  greater  than  or  equal  to  300  mg  protein  per  24  hours.    
Preeclampsia  was  defined  as  severe  if  the  systolic  blood  pressure  exceeded  160  mmHg  
and/or  the  diastolic  blood  pressure  exceeded  110  mmHg,  obtained  on  at  least  two  
separate  occasions,  or  if  the  patient  had  symptoms  of  imminent  eclampsia  (severe  
headache,  visual  disturbance,  epigastric  pain,  hyperreflexia),  or  proteinuria  on  urine  
dipstix  of  3+  or  more.      
Maternal  exclusion  criteria  were  patient  refusal,  any  contraindication  to  spinal  
anaesthesia,  body  mass  index  greater  than  40  kg·m-­2,  clinical  signs  of  hypovolaemia,  
abruptio  placentae,  placenta  praevia,  coagulation  abnormality,  thrombocytopaenia  
(platelet  count  <  75x109·L-­1),  pulmonary  oedema,  local  or  generalised  sepsis,  spinal  
deformity,  umbilical  cord  prolapse,  prior  non-­obstetric  abdominal  surgery,  more  than  2  
previous  caesarean  deliveries,  or  patients  who  were  HIV  positive  and  had  AIDS-­defining  
disease  at  the  time  of  recruitment.    Fetal  exclusion  criteria  were  persistent  fetal  
bradycardia  or  any  other  fetal  condition  contraindicating  spinal  anaesthesia,  gestational  
age  <  28  weeks,  estimated  fetal  weight  <  900  g,  and  twin  pregnancy.    Patients  were  
excluded  from  data  analysis  if  initiation  of  spinal  anaesthetic  took  longer  than  20  minutes;;  
in  this  case,  the  patient  received  general  anaesthesia  and  failure  of  the  technique  was  
recorded.  
Antepartum  management  followed  the  established  protocols  of  our  institution:  if  the  
patient  was  in  established  labour,  an  intravenous  line  was  inserted,  and  a  balanced  
crystalloid  solution  was  administered  at  less  than  100  mL  per  hour.    Patients  not  in  labour  
were  allowed  free  oral  fluids.    Magnesium  sulphate  (MgSO4)  seizure  prophylaxis  was  
administered  to  patients  with  severe  preeclampsia  (intravenous  loading  dose  of  4  g  
followed  by  1  g·h-­1).    Dihydralazine  was  administered  intravenously  for  additional  blood  
pressure  control  according  to  a  standardised  protocol.    Prior  use  of  other  agents  (alpha  
methyldopa,  morphine  and  dexamethasone)  was  recorded.  
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When  a  decision  was  made  to  proceed  to  caesarean  delivery,  the  patient  was  placed  in  
the  left  lateral  position  before  transfer  to  the  operating  theatre;;  40%  oxygen  was  
delivered  by  face-­mask.      
All  patients  received  30-­mL  oral  sodium  citrate  in  theatre,  as  well  as  1-­g  intravenous  
cefazolin  prior  to  induction  of  spinal  anaesthesia.    Monitoring  consisted  of  
electrocardiograph,  non-­invasive  blood  pressure  and  pulse  oximetry.    Baseline  mean  
arterial  pressure  (MAP)  was  recorded  as  the  mean  of  two  non-­invasive  blood  pressure  
readings  not  differing  by  more  than  10%,  measured  in  the  5  minutes  prior  to  induction  of  
spinal  anaesthesia  in  the  left  lateral  position.    After  calculation  of  the  mean  baseline  
blood  pressure,  the  target  value  for  administration  of  vasopressor  was  calculated.    
Thereafter  an  intravenous  fluid  preload  of  300-­mL  hydroxyethyl  starch  (Voluvenâ)  was  
rapidly  administered.    Haemodynamic  data  were  recorded  every  minute  after  initiation  of  
spinal  anaesthesia  until  delivery;;  thereafter  the  time  intervals  for  haemodynamic  
monitoring  until  the  end  of  the  procedure  was  at  the  discretion  of  the  attending  
anaesthesiologist.      
The  management  of  spinal  anaesthesia  was  as  follows:  All  patients  received  2.0  –  
2.2  mL  of  hyperbaric  0.5%  bupivacaine,  with  10  µg  of  fentanyl,  administered  in  the  
sitting  position  at  the  L3/4  interspace  in  the  absence  of  uterine  contractions.  After  
20  seconds  in  the  sitting  position,  patients  were  positioned  supine  with  left  lateral  
tilt,  to  minimise  aortocaval  compression.    Block  height  was  assessed  using  cold  
sensitivity  to  ethyl  chloride  spray,  and  surgery  commenced  when  a  block  level  of  
T4  was  achieved.    All  mothers  received  40%  oxygen  by  face-­mask  during  their  
surgery.  
  
The  management  of  hypotension  was  as  follows:  Patients  were  randomised  to  receive  
either  ephedrine  or  phenylephrine  at  the  time  that  a  vasopressor  was  required.    Blocked  
randomisation  was  used  (randomised  block  sizes  of  4,  6  or  8  using  nquery  Advisor  
Version  6,  Statistical  Solutions,  Cork,  Ireland).    Sealed  envelopes  were  prepared  by  the  
statistician  and  were  opened  if  the  patient  became  hypotensive.    Syringes  were  pre-­
prepared  by  an  investigator  not  involved  with  the  performance  of  the  anaesthesia,  so  that  
the  anaesthetist  was  blinded  as  to  the  vasopressor  given.    Ephedrine  7.5  mg  or  
phenylephrine  50  µg  in  a  volume  of  1,5  mls  each,  was  administered  in  response  to  a  
20%  decrease  from  baseline  mean  arterial  pressure  (MAP)  if  the  MAP  was  also  less  than  
110  mmHg  (target  value).    If  MAP  was  not  restored  to  the  target  value  within  60  –  90  
seconds,  a  second  bolus  of  7.5  -­15  mg  ephedrine  or  50-­100  µg  phenylephrine,  as  per  the  
randomisation  schema,  was  administered.    If  the  target  was  not  achieved  after  a  total  of  
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either  45  mg  of  ephedrine  or  300  µg  of  phenylephrine,  the  alternative  vasopressor  was  
used.    If  the  MAP  at  any  point  decreased  to  more  than  30%  below  baseline,  15  mg  
ephedrine  or  100  µg  phenylephrine  was  administered.    If  heart  rate  decreased  to  less  
than  55  beats  per  minute  in  association  with  hypotension  (MAP  decrease  by  30%  from  
baseline),  ephedrine  10  mg  was  administered,  followed  by  atropine  0.25-­0.5  mg  if  
bradycardia  persisted..      
Twenty  seconds  after  delivery,  oxytocin  3.0  IU  in  3-­mL  saline,  was  administered  over  a  
period  of  60  seconds.    Umbilical  arterial  and  venous  blood  samples  were  collected  from  a  
segment  of  double-­clamped  umbilical  cord  shortly  after  delivery,  and  arterial  and  venous  
blood  gas  parameters  were  determined.    Blood  gas  analysis  was  performed  using  the  
ABL800  Flex  Analyser  (Radiometer  Copenhagen,  Denmark).  
After  delivery,  phenylephrine  50  -­100  µg  or  ephedrine  7.5  –  15  mg  was  administered  in  
boluses  to  maintain  MAP  above  90  mmHg.      
Clinically  relevant  times  were  recorded:    a)  decision  for  caesarean  delivery,  b)  
arrival  in  theatre,  c)  induction  of  anaesthesia  (intrathecal  injection),  d)  uterine  
incision  time,  e)  delivery.    
  
All  maternal  medication  received  in  the  24  hours  prior  to  anaesthesia  were  noted.    
Severity  of  disease  (as  assessed  by  the  degree  of  hypertension  and  the  requirement  for  
vasodilator  and/or  seizure  prophylaxis  therapy,  and  degree  of  proteinuria),  and  presence  
or  absence  of  labour  were  also  recorded.    Maternal  side-­effects,  in  particular  nausea  and  
vomiting,  were  noted.    Neonatal  outcome  was  assessed  by  a  paediatrician  dedicated  to  
the  study,  and  blinded  to  the  vasopressor  used.  
  
The  primary  outcome  was  umbilical  arterial  base  deficit.    Secondary  outcomes  were  
umbilical  arterial  and  venous  pH  and  lactate  level,  venous  base  deficit,  and  Apgar  scores  
at  1  and  5  minutes.    Umbilical  cord  blood  gas  values,  and  other  relevant  anaesthesia  
data  from  patients  not  requiring  vasopressor,  and  for  the  entire  study  cohort,  were  also  
collected.    A  maternal  arterial  blood  gas  specimen  was  obtained  immediately  after  
delivery.    The  number  of  fetuses  with  pH  <  7.2  was  noted,  as  well  as  those  with  UA  base  
deficit  >10  mmol·L-­1.    In  addition,  the  number  of  neonates  requiring  tracheal  intubation  
and/or  who  developed  high-­grade  intraventricular  haemorrhage  or  hypoxic  ischaemic  





The  primary  outcome  variable  was  the  umbilical  arterial  base  deficit.    The  a  priori  sample  
size  was  calculated  as  follows:    A  previous  study  performed  at  our  institution  reported  an  
umbilical  arterial  base  deficit  of  8.7  ±  4.0  mmol·L-­1  during  spinal  anaesthesia  in  patients  
with  severe  preeclampsia  and  a  non-­reassuring  fetal  heart  tracing.    In  this  study,  
ephedrine  was  used  as  the  vasopressor.12  A  between-­group  difference  of  3  mmol.l-­1  was  
hypothesised  as  clinically  relevant  for  the  current  study.    Assuming  a  base  deficit  of  5.7  ±  
3  mmol·L-­1  in  the  comparator  group  (phenylephrine),  31  patients  would  be  required  in  
each  group  for  90%  power  to  detect  this  difference.    Therefore,  the  planned  recruitment  
was  32  patients  who  received  vasopressor  in  each  group.    The  null  hypothesis  was  that  
there  would  be  no  difference  in  umbilical  arterial  base  deficit  in  patients  with  severe  
preeclampsia  who  received  ephedrine  vs  phenylephrine.      The  2  sample  t-­test  was  used  
for  the  statistical  comparison  of  the  two  randomised  groups  with  respect  to  the  primary  
outcome  and  other  continuous  variables  and  the  mean  difference  and  95%  confidence  
intervals  were  estimated.    For  categorical  outcomes,  Fisher’s  exact  test  was  used  to  
compare  the  proportions.    
  
Results  
Details  of  patient  recruitment  are  shown  in  the  CONSORT  diagram  (Figure  1).    A  total  of  
133  patients  were  recruited  to  this  randomised  trial,  and  64  women  were  randomised  to  
receive  either  ephedrine  or  phenylephrine  for  pre-­delivery  spinal  hypotension.    The  initial  
sample  size  calculation  assumed  that  40%  of  patients  would  require  vasopressor  pre-­
delivery.    This  would  have  required  160  patients  for  adequate  power.    However,  64  
patients  required  the  intervention  after  133  patients  had  been  recruited,  so  that  the  study  
was  concluded  at  this  point.    In  the  ephedrine  group,  an  umbilical  venous  sample  could  
not  be  obtained  in  one  patient  and  an  umbilical  arterial  specimen  in  a  second  patient.    
Umbilical  arterial  sampling  failed  in  three  patients  in  the  phenylephrine  group  and  in  one  
patient,  the  maternal  blood  gas  sample  was  venous.    Thus,  for  the  primary  outcome  
variable,  data  from  31  patients  in  the  ephedrine  group  and  29  in  the  phenylephrine  group  
were  compared.    No  patient  was  excluded  because  the  allowed  time  for  spinal  
anaesthesia  was  exceeded,  and  none  required  general  anaesthesia.      
Data  were  also  recorded  in  69  patients  who  did  not  require  vasopressor  therapy.    Four  of  
these  were  excluded  from  statistical  analysis;;  2  were  inappropriately  recruited  (the  
indication  for  caesarean  delivery  was  not  per  protocol)  and  in  a  further  two  there  was  
non-­adherence  to  protocol.    In  the  group  not  requiring  vasopressor  therapy,  umbilical  
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arterial  specimens  were  not  obtainable  in  4  patients.    One  maternal  arterial  blood  gas  
sample  was  not  taken,  and  in  one  case  the  mother  was  breathing  room  air  during  
sampling.      
Demographic  data  and  further  relevant  anaesthesia  data,  including  mean  pre-­delivery  
vasopressor  doses,  are  presented  in  Table  1.    There  were  no  differences  between  
groups  with  respect  to  use  of  non-­study  medications,  numbers  of  patients  in  active  
labour,  severity  of  disease,  gestational  age,  measures  of  fetal  antenatal  condition,  or  
relevant  time  intervals.    All  patients  received  300-­mL  colloid  pre-­delivery,  and  there  was  
no  clinically  significant  haemorrhage.    Two  patients  in  the  ephedrine  group  also  received  
the  alternative  vasopressor  phenylephrine,  100  and  400  µg  respectively,  due  to  a  poor  
initial  pressor  response,  as  per  protocol.    Block  height  ranged  from  T1  to  T6,  and  no  
patient  required  supplemental  analgesia  pre-­delivery.    Figure  2  depicts  pre-­delivery  blood  
pressure  control  in  patients  in  the  ephedrine  and  phenylephrine  groups.  There  were  no  
significant  differences.  
Table  2  shows  details  of  the  umbilical  cord  and  maternal  blood  gas  values,  Apgar  scores  
and  other  neonatal  outcomes.    There  was  no  significant  between-­group  difference  in  
mean  [SD]  umbilical  arterial  base  deficit  in  the  ephedrine  vs  phenylephrine  groups  (-­4.8  
[3.7]  vs  -­6.0  [4.6]  mmol·L-­1  respectively).    The  95%  confidence  interval  of  the  difference  
was  -­1.0  to  3,3  mEq·L-­1;;  P  =  0.29.    There  were  no  differences  in  mean  pH  or  bicarbonate,  
PCO2,  lactate  levels,  or  Apgar  scores  at  1  or  5  minutes.    Eight  patients  in  the  
phenylephrine  (28%)  vs  6  in  the  ephedrine  group  (19%)  had  an  umbilical  arterial  pH  <  
7.2,  and  4  patients  in  each  group  (14%  in  the  phenylephrine  vs  13%  in  the  ephedrine  
group)  had  a  base  deficit  >  10  mmol.l-­1  (NS).    Mean  umbilical  venous  PO2  was  higher  in  
the  ephedrine  group  (2.8  [0.7]  vs  2.4  [0.6]  mmol·L-­1;;  P  =  0.02)  (Figure  3).  
Discussion  
This  randomised  trial  examined  the  effects  on  fetal  acid-­base  status  of  bolus  ephedrine  
versus  phenylephrine  administered  in  response  to  spinal  hypotension  in  patients  with  
severe  preeclampsia  and  a  non-­reassuring  fetal  heart  tracing.    There  were  no  differences  
in  umbilical  arterial  base  deficit,  or  any  of  the  other  indices  of  fetal  acidosis.    The  only  
difference  was  a  higher  umbilical  venous  PO2  in  the  group  randomised  to  ephedrine.    
Importantly,  there  were  no  differences  in  Apgar  scores  or  other  clinical  outcomes.    This  is  
in  agreement  with  other  studies  in  non-­elective  caesarean  delivery.    This  study  is  
however  unique  in  that  it  was  specifically  designed  to  assess  neonates  with  potential  fetal  
compromise  born  to  mothers  with  established  severe  preeclampsia.    This  group  is  at  
particularly  high  risk  of  uteroplacental  insufficiency,  and  therefore  concern  exists  
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regarding  the  possible  effects  of  vasopressors  on  the  uteroplacental  circulation.  The  
results  of  this  study  employing  vasopressors  by  bolus  administration  are  consistent  with  
the  results  of  a  parallel  study  performed  at  Northwestern  University  (Chicago,  IL,  USA),  in  
which  women  with  preeclampsia  undergoing  caesarean  delivery  under  spinal  
anaesthesia  were  randomised  to  receive  a  phenylephrine  or  ephedrine  infusion  to  
prevent  the  development  of  hypotension.13      The  investigators  for  both  studies  
collaborated  on  the  design,  analysis  and  reporting  of  the  studies.      
  
The  two  vasopressors  predominantly  in  use  in  clinical  practice  are  the  mixed  alpha-­  and  
beta-­adrenergic  agonist  ephedrine  and  the  direct  acting  alpha-­adrenergic  agonist  
phenylephrine.    A  significant  body  of  work  in  healthy,  non-­labouring  women  undergoing  
elective  caesarean  delivery  has  found  that  neonates  whose  mothers  were  given  
phenylephrine  for  the  treatment  of  spinal  hypotension,  had  higher  umbilical  arterial  pH  
values  that  those  whose  mothers  were  treated  with  ephedrine.    A  recent  systematic  
review  and  cumulative  meta-­analysis  clearly  demonstrated  a  decreased  risk  for  fetal  
acidosis  with  phenylephrine  administered  to  healthy  mothers  undergoing  elective  
caesarean  delivery.    The  relative  risk  of  fetal  acidosis  (pH  <7.2)  was  5.29  for  ephedrine  
vs  phenylephrine  (P  =  0.006).1        
The mechanism of acidosis was elucidated by Ngan Kee and colleagues.2  In a 
randomised comparison, patients receiving ephedrine by continuous infusion had not 
only lower umbilical arterial and venous pH and a higher base excess than those 
receiving phenylephrine infusions, but also higher umbilical arterial and venous plasma 
concentrations of lactate, glucose, adrenaline and noradrenaline.  Placental transfer was 
significantly greater for ephedrine than phenylephrine, supporting the hypothesis that the 
effects of ephedrine on acid-base status are due to direct stimulation of fetal β-adrenergic 
receptors, resulting in an increase in metabolic rate. 
The  total  dose  of  ephedrine  appears  to  correlate  with  worsening  fetal  acid-­base  status.6,  
14    However,  even  at  lower  doses,  there  is  still  a  trend  towards  a  lower  fetal  pH.15    It  is  
possible  that  some  fetuses  are  at  higher  risk  of  clinically  significant  acidosis  in  response  
to  small  doses  of  ephedrine  based  on  their  genetic  profile,  in  particular  the  β2-­
adrenoreceptor  haplotype.3      
It  is  important  to  consider  the  possible  adverse  effects  that  vasopressor  treatment  could  
have  on  a  fetus  with  actual  or  potential  compromise.    A  fetus  with  a  compromised  
uteroplacental  circulation  may  not  be  able  to  compensate  for  any  further  reduction  in  flow  
due  to  vasoconstriction  or  decreased  maternal  cardiac  output  induced  by  vasopressor  
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therapy.    Equally,  the  fetus  may  not  be  able  to  cope  with  the  increase  in  oxygen  demand  
as  a  result  of  ephedrine-­induced  increases  in  metabolism.    
  
There  are  a  limited  number  of  randomised  trials  examining  the  effects  of  bolus  
phenylephrine  vs  ephedrine  in  non-­elective  caesarean  delivery.    Ngan  Kee  and  
colleagues  found  similar  UA  and  UV  pH  and  base  excess  between  groups.4    UA  and  UV  
lactate  levels  were  higher  in  the  ephedrine  group.    UV  and  UA  PO2  were  lower  in  the  
phenylephrine  group,  but  O2  content  was  similar.    There  were  no  differences  in  Apgar  
scores  and  clinical  outcome.    The  authors  concluded  that  either  vasopressor  was  
acceptable  in  the  setting  of  non-­elective  caesarean  delivery.    Importantly,  the  enrolled  
patients  were  ASA  physical  status  1  or  2  with  term  pregnancies,  and  none  had  
preeclampsia.    The  total  vasopressor  dose  was  low  in  comparison  to  previous  studies  in  
healthy  women  undergoing  elective  procedures.    Of  148  patients  receiving  vasopressor  
therapy,  30  were  deemed  to  have  fetal  compromise.    Sub-­analysis  of  this  group  showed  
that  UA  PO2  was  lower  in  the  phenylephrine  group,  but  all  other  blood  gas  parameters  
were  similar.    It  was  postulated  that  these  differences  in  PO2  may  reflect  
vasoconstriction,  reduced  uteroplacental  flow  and  increased  efficiency  of  oxygen  
extraction,  which  may  act  as  a  safety  mechanism  preventing  an  adverse  impact  of  
phenylephrine  on  fetal  acidosis  or  Apgar  scores.    The  finding  of  a  lower  UV  PO2  in  the  
phenylephrine  group  has  also  been  shown  in  the  elective  setting.2  16    Our  study  also  
found  a  statistically,  but  not  clinically  significantly  higher  UV  PO2  in  the  ephedrine  group.    
  
A  more  recent  study  compared  ephedrine  8  mg  and  phenylephrine  100  μg  in  a  group  of  
healthy  patients  undergoing  emergency  caesarean  delivery  for  fetal  compromise.7    They  
found  no  between-­group  differences  in  UA  and  UV  pH,  PO2,  PCO2,  BE,  or  the  incidence  
of  fetal  acidosis.    Apgar  scores  and  early  fetal  outcome  were  also  comparable.  
  
Cooper5  published  a  retrospective  study  of  the  association  between  choice  of  
vasopressor  and  fetal  pH  during  high-­risk  caesarean  delivery  for  various  indications.    UV  
PO2  was  again  higher  in  the  ephedrine  group.    UA  pH  was  similar  whether  ephedrine  or  
phenylephrine  was  used.    The  only  variable  associated  with  a  low  fetal  pH  was  a  non-­
reassuring  fetal  heart  rate  tracing.    They  concluded,  in  agreement  with  previous  studies,  
that  the  likely  reason  for  the  similar  pH  between  groups  was  that  a  lower  total  dose  of  
ephedrine  (mean  12  mg  [IQR  6-­18  mg])  had  been  given  in  comparison  with  studies  in  
elective  cases.      
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There  is  only  one  retrospective  comparison  of  bolus  administered  ephedrine  and  
phenylephrine  for  the  treatment  of  spinal  hypotension  in  preeclampsia.6    This  study  
showed  no  difference  in  pH,  base  excess,  1-­  and  5-­min  Apgar  scores,  or  the  number  of  
neonates  with  an  UA  pH  <7.2.    There  were  significant  differences  between  the  two  
groups  in  terms  of  patient  characteristics:  gestational  age  and  birth  weight  of  the  
neonates,  the  indications  for  caesarean  delivery,  and  the  total  equivalent  doses  of  
vasopressor.    However,  on  multivariate  regression  analysis,  a  non-­reassuring  fetal  heart  
tracing  was  the  only  variable  associated  with  a  low  UA  pH.    By  comparison,  the  patients  
in  the  present  trial  all  had  severe  features  of  preeclampsia,  and  most  had  early  onset  
disease,  with  a  mean  gestational  age  of  33  weeks.  
  
A  concern  associated  with  our  study  was  the  necessity  to  obtain  consent  at  short  notice  
before  the  procedure;;  this  was  done  in  a  sensitive  and  empathetic  manner,  and  was  also  
made  easier  by  virtue  of  the  straightforward  intervention  of  the  study.    The  small  
imbalance  in  sample  size  due  to  difficulties  in  obtaining  umbilical  arterial  specimens  in  3  
cases,  did  not  affect  the  estimated  difference  in  the  primary  outcome.      
  
Saravanan  et  al  reported  a  potency  ratio  for  equivalence  between  phenylephrine  and  
ephedrine  infusions  of  80:1  in  healthy  women  undergoing  elective  caesarean  delivery  
after  36  weeks’  gestation.17  There  is  no  data  on  the  relevant  potency  difference  in  
preterm  severe  preeclamptic  patients.    The  ratio  of  the  ephedrine  to  phenylephrine  dose  
used  in  this  study  was  based  on  our  clinical  experience  of  managing  spinal  hypotension  
in  many  similar  cases;;  Figure  2  shows  that  the  blood  pressure  control  was  similar  in  the  
two  groups.  
  
In  conclusion,  the  important  finding  of  this  study  is  that  fetal  acid-­  base  status  is  
independent  of  whether  phenylephrine  or  ephedrine  is  used  as  a  bolus  to  treat  spinal  
hypotension  in  patients  with  severe  preeclampsia.    The  choice  of  vasopressor  should  be  
based  upon  maternal  haemodynamic  response  in  the  individual  case.    






   1.     Veeser  M,  Hofmann  T,  Roth  R,  Klohr  S,  Rossaint  R,  Heesen  M.  Vasopressors  for  the  
management  of  hypotension  after  spinal  anesthesia  for  elective  caesarean  section.  
Systematic  review  and  cumulative  meta-­analysis.  Acta  Anaesthesiol  Scand  2012;;  56:  810-­
16  
   2.     Ngan  Kee  WD,  Khaw  KS,  Tan  PE,  Ng  FF,  Karmakar  MK.  Placental  transfer  and  fetal  
metabolic  effects  of  phenylephrine  and  ephedrine  during  spinal  anesthesia  for  cesarean  
delivery.  Anesthesiology  2009;;  111:  506-­12  
   3.     Landau  R,  Liu  SK,  Blouin  JL,  Smiley  RM,  Ngan  Kee  WD.  The  effect  of  maternal  and  fetal  
beta2-­adrenoceptor  and  nitric  oxide  synthase  genotype  on  vasopressor  requirement  and  
fetal  acid-­base  status  during  spinal  anesthesia  for  cesarean  delivery.  Anesth  Analg  2011;;  
112:  1432-­37  
   4.     Ngan  Kee  WD,  Khaw  KS,  Lau  TK,  Ng  FF,  Chui  K,  Ng  KL.  Randomised  double-­blinded  
comparison  of  phenylephrine  vs  ephedrine  for  maintaining  blood  pressure  during  spinal  
anaesthesia  for  non-­elective  Caesarean  section.  Anaesthesia  2008;;  63:  1319-­26  
   5.     Cooper  DW,  Sharma  S,  Orakkan  P,  Gurung  S.  Retrospective  study  of  association  between  
choice  of  vasopressor  given  during  spinal  anaesthesia  for  high-­risk  caesarean  delivery  and  
fetal  pH.  Int  J  Obstet  Anesth  2010;;  19:  44-­9  
   6.     Ituk  US,  Cooter  M,  Habib  AS.  Retrospective  comparison  of  ephedrine  and  phenylephrine  
for  the  treatment  of  spinal  anesthesia  induced  hypotension  in  pre-­eclamptic  patients.  
Current  Medical  Research  and  Opinion  2016;;  32:  1083-­86  
  
      7.    Mohta  M,  Aggarwal  M,  Sethi  AK,  Harisinghani  P,  Guleria  K.  Randomised  double-­blind  
comparison  of  ephedrine  and  phenylephrine  for  management  of  post-­spinal  hypotension  in  
potential  fetal  compromise.  Int  J  Obstet  Anesth  2016;;  27:32-­40  
  
   8.     Aya  AG,  Mangin  R,  Vialles  N,  Ferrer  JM,  Robert  C,  Ripart  J,  de  La  Coussaye  JE.  Patients  
with  severe  preeclampsia  experience  less  hypotension  during  spinal  anesthesia  for  
elective  cesarean  delivery  than  healthy  parturients:  a  prospective  cohort  comparison.  
Anesth  Analg  2003;;  97:  867-­72  
   9.     Dyer  RA,  Piercy  JL,  Reed  AR,  Lombard  CJ,  Schoeman  LK,  James  MF.  Hemodynamic  
changes  associated  with  spinal  anesthesia  for  cesarean  delivery  in  severe  preeclampsia.  
Anesthesiology  2008;;  108:  802-­11  
10.      National  Institute  for  Health  and  Care  Excellence  (NICE),  2014.  Intrapartum  care  for  healthy  
women  and  babies  during  childbirth.  Clinical  Guideline  109;;  1.10.    London:  NICE    
https://www.nice.org.uk/guidance/cg190/chapter/Recommendations#monitoring-­during-­
labour  
  11.     Hypertension  in  pregnancy.    Report  of  the  American  College  of  Obstetricians  and  
Gynecologists'  Task  Force  on  Hypertension  in  Pregnancy.  Obstetrics  and  Gynecology  
2013;;  122:  1122-­31    
  
 42 
  12.     Dyer  RA,  Els  I,  Farbas  J,  Torr  GJ,  Schoeman  LK,  James  MF.  Prospective,  randomized  trial  
comparing  general  with  spinal  anesthesia  for  cesarean  delivery  in  preeclamptic  patients  
with  a  nonreassuring  fetal  heart  trace.  Anesthesiology  2003;;  99:  561-­69  
  
13.    Higgins  N,  Fitzgerald  PC,  van  Dyk  D,  Dyer  RA,  McCarthy  RJ,  Wong  CA.  The  effect  of  
prophylactic  phenylephrine  and  ephedrine  infusions  on  umbilical  artery  blood  pH  in  women  
with  preeclampsia  undergoing  caesarean  delivery  with  spinal  anaesthesia:  a  randomised  
double-­blind  trial.  Submitted  for  publication,  Br  J  Anaesth  Jan  2017  
                     
14.      Cooper  DW,  Gibb  SC,  Meek  T  et  al.  Effect  of  intravenous  vasopressor  on  spread  of  spinal  
anaesthesia  and  fetal  acid-­base  equilibrium.  Br  J  Anaesth  2007;;  98:  649–56  
  
15.      Dyer  RA,  Biccard  B.  Ephedrine  for  spinal  hypotension  during  elective  caesarean  section:  
the  final  nail  in  the  coffin?  Acta  Anaesthesiol  Scand  2012;;  56:  807–9  
  
16.      Ngan  Kee  WD,  Lee  A,  Khaw  KS,  Ng  FF,  Karmakar  MK,  Gin  T.  A  randomized  double-­
blinded  comparison  of  phenylephrine  and  ephedrine  infusion  combinations  to  maintain  
blood  pressure  during  spinal  anesthesia  for  cesarean  delivery:  the  effects  on  fetal  acid-­
base  status  and  hemodynamic  control.  Anesth  Analg  2008;;  107:  1295–302  
  
17.     Saravanan  S,  Kocarev  M,  Wilson  RC,  Watkins  E,  Columb  MO,  Lyons  G.  Equivalent  dose      
of  ephedrine  and  phenylephrine  in  the  prevention  of  post-­spinal  hypotension  in  Caesarean  

























Table  1.  Patient  Characteristics  and  Intra-­operative  Data  
 






Age,  years  [Mean  (SD)]   26  (6)   24  (6)   26  (6)  
BMI,  kg.m-­2  [Mean  (SD)]   30  (6)   29  (6)   32  (6)  
Gravidity,  median  (range)   2  (1-­5)   1  (1-­5)   2  (1-­5)  
Parity,  median  (range)   0  (0-­4)   0  (0-­4)   1  (0-­3)  
MgSO4  therapy  (n)   115  (89%)   29  (90%)   31  (97%)  
Hydralazine  therapy  (n)   58  (45%)   16  (50%)   17  (53%)  
In  labour  (n)   25  (19%)   5  (15%)   9  (28%)  
Baseline  MAP,  [Mean  (SD)]   127(14)   128  (14)   128  (15)  
SBP  >  160  mmHg  (n)   121  (94%)   30  (94%)   30  (94%)  
Proteinuria  3-­4  +  (n)   98  (76%)   19  (60%)   28  (88%)  
Gestational  age,  weeks  [Mean  (SD)]   32.7  (3.3)   33.0  (3.7)   33.6  (3.6)  
Neonatal  weight,  g  [Mean  (SD)]   1676  (747)   1744  (787)   1988  (860)  
Amniotic  fluid  index,  abnormal  (n)   10  (8%)   2  (6%)   0  
UA  doppler  resistance  index:           
No.  with  RI  >  95th  percentile  for  
gestational  age  
2  (1.5%)   0   0  
No.  with  absent  end  diastolic  flow   6  (5%)   1  (3%)   0  
No.  with  reversed  end  diastolic  flow   1  (0.8%)   1  (3%)   0  
Placental  weight,  g  [Mean  (SD)]   380  (135)   392  (120)   420  (139)  
TOTI,  min   19  (6)   18  (5)   19  (5)  
TIUI,  min   12  (3)   12  (3)   12  (3)  
TUID,  sec   57  (42)   54  (29)   66  (64)  
D-­D  interval,  min  
  
67  (33)   62  (23)   70  (32)  
Nausea  (n)   5  (4%)   1  (3%)   2  (6%)  
Vomiting  (n)   9  (7%)   5  (15%)   2  (6%)  
Ephedrine  pre-­delivery,  mg    
[median  (  range)]  
n/a   15  (7.5  –  45)   n/a  
Phenylephrine  pre-­delivery,  μg  
[median  (range)]  
n/a   n/a   100  (50-­650)  
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MAP  –  mean  arterial  pressure,  SBP  –  systolic  blood  pressure,  RI  –  resistance  index,  TOTI  -­  time  from  
arrival  in  theatre  to  induction  of  spinal  anaesthesia,  TIUI  -­  time  from  induction  of  spinal  anaesthesia  to  
uterine  incision,  TUID  -­  time  from  uterine  incision  to  delivery,  D-­D  -­  decision  to  delivery  interval  
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    Table  2.  Blood  gas  data  and  neonatal  outcome  
 
  










95%  CI   P  
value  
Neonatal  umbilical  








        
pH   7.25  (0.09)   7.25  (0.08)   7.22  (0.10)   0.03   -­0.02  to  0.08   .22  
PCO2  (kPa)   6.9  (1.37)   6.72  (1.29)   7.00  (1.58)   -­0.28   -­1.02  to  0.46   .45  
PO2  (kPa)   1.66  (0.7)   1.92  (0.78)   1.71  (0.76)   0.21   -­0.19  to  0.62   .30  
Base  excess  (mmol.l-­1)   -­4.35  (4.08)   -­4.81  (3.73)   -­5.97  (4.60)   1.16   -­1.00  to  3.32   .29  
Standard  bicarbonate  
(mmol.l-­1)  
18.5  (3.06)   18.1  (3.02)   17.5  (3.48)   0.64   -­1.04  to  2.32   .45  
Lactate  (mmol.l-­1)  
  
3.56  (2.36)   3.76  (2.20)   3.82  (2.81)   -­0.06   -­1.37  to  1.25   .93  
Neonatal  umbilical  
venous  [mean  (SD)]  
n=128   n=31   n=32           
pH   7.28  (0.08)   7.28  (0.07)   7.27  (0.10)   0.01   -­0.03  to  0.06   .55  
PCO2  (kPa)   6.23  (1.3)   6.20  (1.24)   6.31  (1.34)   -­0.11   -­0.76  to  0.54   .74  
PO2  (kPa)   2.53  (0.73)   2.79  (0.68)   2.39  (0.62)   0.39   0.06  to  0.72   .02  
Base  excess  (mmol.l-­1)   -­4.84  (2.77)   -­4.65  (3.89)   -­5.36  (3.60)   0.72   -­1.17  to  2.61   .45  
Standard  bicarbonate  
(mmol.l-­1)  
19  (2.96)   18.9  (3.16)   18.2  (3.05)   0.64   -­0.93  to  2.22   .42  
Lactate  (mmol.l-­1)  
  
3.25  (2.29)   3.41  (2.18)   3.28  (2.44)   0.14   -­1.04  to  1.32   .81  
Maternal  arterial  
[mean  (SD)]  
n=127   n=32   n=30           
pH   7.41  (0.03)   7.39  (0.04)   7.40  (0.03)   -­0.01   -­0.02  to  0.01   .57  
PCO2  (kPa)   4.07  (0.47)   4.11  (0.42)   3.94  (0.53)   0.17   -­0.07  to  0.41   .17  
PO2  (kPa)   17  (5.94)   17.1  (5.07)   17.7  (6.62)   -­0.60   -­3.50  to  2.40   .71  
Base  excess  (mmol.l-­1)   -­4.84  (2.77)   -­5.67  (2.57)   -­6.05  (3.0)   0.38   -­1.02  to  1.79   .59  
Standard  bicarbonate  
(mmol.l-­1)  
20.8  (2.2)   20.1  (2.13)   19.9  (2.30)   0.30   -­0.90  to  1.40   .64  
Lactate  (mmol.l-­1)   1.32  (0.56)   1.60  (0.53)   1.34  (0.55)   0.27   -­0.01  to  0.54   .06  





                  
        
UApH  <  7.2  (n)   20/125  (16%)   6/31  (19%)   8/29  (28%)   -­8.2%   -­29.6  to  13.2%   .45  
UA  base  excess  
  >10  mmol.l-­1  (n)  
11/125  (9%)   4/31  (13%)   4/29  (14%)   -­1.0%   -­18.1  to  16.3%   .92  
1  min  Apgar    
(median  [range])  
8  [2-­10]   8  [4-­10]   8  [4-­9]           
1  min  Apgar  <7  (n)   41  (32%)   10  (31%)   12  (38%)   -­6.3%   -­29.5  to  17.0%   .60  
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UA  –  umbilical  arterial,  OT  -­  operating  theatre,  NICU  –  neonatal  intensive  care  unit,    
IVH  -­  intra-­ventricular  haemorrhage,  HIE  -­  hypoxic  ischaemic  encephalopathy  
  
5  min  Apgar  score  
(median  [range])  
9  [4-­10]   9  [7-­10]   9  [7-­10]           
5  min  Apgar  <7  (n)   3  (2%)   0   0           
Intubation  in  OT  (n)   0   1  (3%)   0           
Mortality  prior  to  
discharge  from  NICU  (n)  
3  (2%)   0   0           
IVH  grade  3  or  4  (n)  
  
3  (2%)   0   0              
HIE  (n)  
  
0   0   0           
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Assessed  for  eligibility  and  
underwent  initial  enrollment  
(n=135)  
Excluded  (n=2)  
¨Declined  to  participate  (n=0)  
¨Failed  spinal  anaesthesia  (n=2)  
Analysed  (n=32)  
¨Analysed  with  incomplete  data  (n=2)  
• Umbilical  venous  sample  not  obtained  
(n=1)  
• Umbilical  arterial  sample  not  obtained  
(n=1)  
  
Analysed  for  primary  outcome    (n=31)  




Completed  study  protocol  (n=32)    
Allocated  to  ephedrine  (n=32)  
¨ Received  allocated  intervention  
(n=32) 
 
Allocated  to  phenylephrine  (n=32)  




¨Analysed  with  incomplete  data  (n=5)    
• Maternal  arterial  sample  not  obtained  
(n=2)  
• Umbilical  arterial  sample  not  obtained  
(n=3)    
  
Analysed  for  primary  outcome  (n=  29)  








Required  a  vasopressor?  
  No  Intervention  (n=69)  
Analysed    (n=65)  
¨ Excluded  from  analysis  (n=2)  
• Indication  for  CD  not  per  protocol  
¨Analysed  with  incomplete  data  (n=6)  
• Umbilical  arterial  gas  not  obtained  
(n=4)  
• Maternal  arterial  sample  not  obtained  
(n=1)  
• Maternal  arterial  sample  obtained  
while  breathing  room  air  (n=1)  
yes no 
Completed  study  protocol  (n=32)     Completed  study  protocol  (n=65)  
Non-­adherence  to  protocol  (n=2)  
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Figure  3:  Comparison  of  umbilical  arterial  and  venous  PO2  values  
  
  
Box  and  whisker  plot  showing  median,  interquartile  range,  and  range  of  values.  
*Median  neonatal  venous  PO2  significantly  higher  in  the  ephedrine  group  
Ephe  =  Ephedrine;;  Phen  =  Phenylephrine  
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PREPARING  YOUR  MANUSCRIPT  
The  standard  layout  of  a  manuscript  is:    
•  Title  page    
•  Summary,  including  Keywords    
•  Introduction  (not  headed)    
•  Methods    
•  Results    
•  Discussion    
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•  Details  of  authors  contributions    
•  Acknowledgements    
•  Declaration  of  interests    
•  Funding    
•  List  of  references    
•  Tables  (including  legends  to  tables)    
•  Legends  to  illustrations    
The  pages  should  be  numbered  in  the  top  right-­hand  corner,  the  title  page  being  page  one,  etc.  
Start  each  section  on  a  separate  page.  
TITLE  PAGE  
A  separate  page  which  includes  the  title  of  the  paper.  Titles  should  provide  a  reasonable  
indication  of  the  contents  of  the  paper.  This  is  important  as  some  search  engines  use  the  title  for  
searches.  Therefore,  it  is  best  to  avoid  enigmatic  or  vague  titles  such  as  'An  unusual  cause  of  
hypotension'.  Titles  in  the  form  of  a  question,  such  as  'Is  propofol  epileptogenic?'  may  be  
acceptable.  
The  title  page  should  include  the  name(s)  and  address(es)  of  all  author(s).  It  should  be  made  
clear  which  address  refers  to  which  author.  Details  of  the  authors’  qualifications  and  post  (e.g.,  
consultant,  senior  lecturer)  are  not  required.  An  author's  present  address,  if  it  differs  from  that  at  
which  the  work  was  carried  out,  or  special  instructions  concerning  the  address  for  
correspondence,  should  be  given  as  a  footnote  on  the  title  page  and  referenced  at  the  
appropriate  place  in  the  author  list  by  superscript  numbers  (  1  2  3  etc.)  If  the  address  to  which  
proofs  should  be  sent  is  not  that  of  the  first  author,  clear  instructions  should  be  given  in  a  
covering  note,  not  on  the  title  page.  
All  authors  should  follow  the  criteria  for  ‘authorship’  as  determined  by  International  Committee  of  
Medical  Journal  Editors.  For  details,  please  refer  to  section  on  British  Journal  of  Anaesthesia  
Policies.    
A  short  running  title  containing  not  more  than  50  characters  (including  spaces)  should  be  
included.  
SUMMARY  (ABSTRACT)  
The  Summary  (Abstract)  will  be  printed  at  the  beginning  of  the  paper.  It  should  be  on  a  separate  
sheet,  in  structured  format  (Background;;  Methods;;  Results;;  and  Conclusions)  for  all  Clinical  
Investigations  and  Laboratory  Investigations.  For  Reviews  and  Case  Reports,  the  Abstract  
should  not  be  structured.  
The  Abstract  should  give  a  succinct  account  of  the  study  or  contents,  in  up  to  250  words.  The  
Results  section  should  contain  data.  It  is  important  that  the  results  and  conclusion  given  in  the  
Abstract  are  the  same  as  in  the  whole  article,  as  the  Abstract  may  be  used,  as  it  stands,  by  




Three  to  five  keywords  should  be  included  on  the  summary  page  under  the  heading  Keywords.  
They  should  be  in  alphabetical  order  and  must  be  classified  according  to  MESH  keywords.  
These  can  be  found  here  .  Please  note  that  UK  English  spelling  will  be  used  for  these.  Please  do  
not  simply  list  words  you  think  are  key.  For  example,  propofol  should  be  listed  as:  anaesthetics  
i.v.,  propofol;;  
TRIAL  REGISTRY  NUMBER  
For  Clinical  Trials  (also  see  below),  please  include  the  trial  registry  number  under  a  separate  
heading  after  Keywords.  
INTRODUCTION  
The  recommended  structure  for  this  section  is;;    
•  Background  to  the  subject    
•  What  is  known  /  unknown  about  it    
•  What  bit  you  are  interested  in  /  hypothesis    
•  Aim  of  your  study    
As  a  rule,  the  introduction  to  a  paper  should  not  require  more  than  about  200  words  and  have  a  
maximum  of  1.5  pages  double-­spaced.  The  introduction  should  give  a  concise  account  of  the  
background  of  the  problem  and  the  object  of  the  investigation.  It  should  state  what  is  known  of  
the  problem  to  be  studied  at  the  time  the  study  was  started.  Previous  work  should  be  quoted  
here  but  only  if  it  has  direct  bearing  on  the  present  problem.  For  example,  a  description  and  
evaluation  of  an  analgesic  infusion  as  part  of  an  intravenous  anaesthesia  regimen  need  not  
include  an  exhaustive  account  of  the  previous  literature  addressing  the  problems  of  intravenous  
anaesthesia  and  the  many  studies  of  different  analgesics,  etc.    
The  final  paragraph  should  clearly  state  the  primary  and,  if  applicable,  secondary  aims  of  the  
study.    
If  a  preliminary  account  of  the  results  has  been  given  in  a  published  abstract,  it  is  customary  to  
refer  to  this.  
METHODS  
The  Methods  section  should  give  a  clear  but  concise  description  of  the  process  of  the  study.  
Subjects  covered  in  this  should  include:    
•  Ethics  approval  /  licence    
•  Patient  population    
•  Inclusion  /  exclusion  criteria    
•  Conduct  of  the  study    
•  Data  handling    
•  Statistics    
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•  (CTA)  
Ethics  approval  /  licence    
Regardless  of  the  country  of  origin,  all  clinical  investigators  describing  human  research  must  
abide  by  the  Ethical  Principles  for  Medical  Research  Involving  Human  Subjects  outlined  in  the  
Declaration  of  Helsinki,  and  adopted  in  October  2000  by  the  World  Medical  Association.  This  
document  can  be  found  at  http://www.wma.net/en/30publications/10policies/b3/.  Investigators  
are  encouraged  to  read  and  follow  the  Declaration  of  Helsinki.  Clinical  studies  that  do  not  meet  
the  Declaration  of  Helsinki  criteria  will  be  denied  peer  review.  If  published  research  is  
subsequently  found  to  be  non-­compliant  it  will  be  withdrawn  or  retracted.  
On  the  basis  of  the  Declaration  of  Helsinki,  the  British  Journal  of  Anaesthesia  requires  that  all  
manuscripts  reporting  clinical  research  state  in  the  first  paragraph  of  the  Methods  section  that:    
•  The  study  was  approved  by  the  appropriate  Ethics  authority.    
•  Written  informed  consent  was  obtained  from  all  subjects,  a  legal  surrogate,  or  the  parents  or  
legal  guardians  for  minor  subjects,  or  that  the  requirement  for  written  informed  consent  was  
waived  by  the  ethics  committee.  
Human  subjects  should  not  be  identifiable.  Do  not  disclose  patients’  names,  initials,  hospital  
numbers,  dates  of  birth,  or  other  protected  healthcare  information.  Keep  copies  of  ethics  
approval  and  written  informed  consents.  In  unusual  circumstances  the  editors  may  request  
blinded  copies  of  these  documents  to  address  questions  about  ethics  approval  and  study  
conduct.  
This  section  must  include  the  Clinical  Trials  Authorization  as  all  studies  must  be  registered,  as  
per  the  EU  directive  on  clinical  trials  which  came  into  force  on  1st  May  2004.  There  are  a  
number  of  trial  registration  sites  including  EudraCT  (http://eudract.emea.europa.eu  )  From  
January  2009  studies  published  in  the  British  Journal  of  Anaesthesia  must  include  the  trial  
registration  number  in  the  Methods.    
Example;;  The  study  was  approved  by  the  X  regional  research  ethics  committee  (Ref:  
07/A123/456)  and  registered  with  EudraCT  (ref:  2007:123456:AA).    
For  more  details  about  Clinical  Trials,  please  see  section  below.  
The  title  of  this  section  should  be  'Methods'.  'Materials  and  methods'  or  'Patients  and  methods'  
should  not  be  used.  While  brevity  is  essential,  the  methods  must  be  described  in  sufficient  detail  
to  allow  the  experiment  to  be  interpreted,  and  repeated  if  necessary,  by  the  reader.  Previously  
documented  standard  methods  need  not  be  recounted  in  detail,  but  appropriate  reference  to  the  
original  should  be  cited.  Where  the  programme  of  research  is  complex  such  as  might  occur  in  a  
cardiovascular  study  in  animals,  it  may  be  preferable  to  provide  a  table  or  figure  to  illustrate  the  
plan  of  the  experiment,  thus  avoiding  a  lengthy  explanation.  
Sometimes  detailed  laboratory  techniques  may  be  filed  separately  in  a  recognized  library  and  a  
note  to  this  effect  given  in  the  manuscript.  Where  measurements  are  made,  an  indication  of  the  
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error  of  the  method  in  the  hands  of  the  author  should  be  given.  The  name  of  the  manufacturer  of  
instruments  used  for  measurement  should  be  given  with  an  appropriate  catalogue  number  or  
instrument  identification  (e.g.  Radiometer  PHM  7).  The  manufacturer's  town  and  country  must  
be  provided.  In  the  case  of  solutions  for  laboratory  use,  the  methods  of  preparation  and  precise  
concentration  should  be  stated.  
DRUGS  
When  a  drug  is  first  mentioned,  it  should  be  given  by  the  international  non-­proprietary  name,  
followed  by  the  chemical  formula  in  parentheses  if  the  structure  is  not  well  known,  and  (if  
relevant)  by  the  proprietary  name  (with  an  initial  capital  letter).  A  figure  giving  the  molecular  
configuration  of  the  drug  is  necessary  only  in  the  case  of  the  earliest  reports  of  a  new  drug.  The  
author  should  indicate  in  an  accompanying  note  to  the  editor  the  source  from  which  he  has  
obtained  the  molecular  configuration;;  it  is  an  important  requirement  that  the  author  should  check  
the  accuracy  of  the  configuration  in  every  detail.  Drug  dosages  are  normally  given  by  the  name  
of  the  drug  followed  by  the  dose  (e.g.  propofol  2.5  mg  kg  -­1  ).  Do  not  confuse  drug  dose  with  
concentration.  
MULTIPLE  PUBLICATIONS  OF  HUMAN  OR  ANIMAL  TRIALS  
In  the  interest  of  minimizing  the  risk  to  human  and  animal  subjects,  as  well  as  promoting  efficient  
use  of  scarce  research  funds,  investigators  will  sometimes  pose  several  questions  and  make  
multiple  measurements  in  a  single  study,  with  the  intent  of  publishing  multiple  manuscripts.  This  
may  be  a  laudable  practice,  or  it  may  be  an  inappropriate  attempt  to  slice  a  single  study  into  
'minimum  publishable  units'.  Division  of  data  from  a  single  research  study  into  multiple  
manuscripts  is  acceptable,  provided  three  requirements  are  met:  
1.  The  cover  letter  for  every  paper  derived  from  the  study  explains  the  need  for  dividing  the  
study  into  multiple  manuscripts.  This  applies  even  if  only  one  of  the  submissions  is  to  the  British  
Journal  of  Anaesthesia  .  It  is  essential  that  the  cover  letter  states  that  other  parts  of  the  study  are  
currently  under  consideration  or  in  press  with  another  journal.  The  Journal  will  consider  the  
appropriateness  of  the  division  as  part  of  the  review  process.  
2.  In  all  manuscripts  after  the  first,  the  investigator  must  disclose  that  the  subjects  reported  in  the  
study  have  been  previously  reported,  with  appropriate  citation  to  the  first  manuscript.  This  
practice  is  essential  for  scientific  continuity.  For  example,  should  a  question  arise  about  the  
conduct  of  the  study  in  one  manuscript,  readers  should  be  able  to  identify  all  manuscripts  based  
on  the  same  experimental  data.  
3.  Measurements  must  not  interfere  with  each  other.  Such  interference  may  happen  in  ways  that  
are  not  evident  at  the  time  of  the  study.  For  example,  measurements  of  pain  thresholds  may  
make  it  impossible  to  measure  sedative  effects.  The  potential  for  interfering  measurements  may  
not  be  evident  if  the  pain  thresholds  and  sedation  effects  are  reported  in  separate  manuscripts  




Data  on  the  mean  age  (range),  weight,  sex,  height,  criteria  for  selection,  etc.  (  patient  
characteristics,  not  demographics  )  should  be  presented,  with  an  indication  of  the  general  state  
of  health  and  type  of  operation  being  undertaken.  Animal  data  on  sex,  strain  and  weight  should  
be  included.  Although  it  is  usually  possible  to  make  such  a  statement  in  a  short  paragraph,  more  
complex  information  may  be  preferable  as  a  table.  However,  tables  and  figures  are  expensive  to  
produce  and  should  not  be  used  unnecessarily.  Where  it  has  been  necessary  to  seek  
permission  from  the  patients  for  the  type  of  study  being  undertaken,  this  should  be  indicated.  
CLINICAL  TRIALS  
In  accordance  with  the  Clinical  Trial  Registration  Statement  from  the  International  Committee  of  
Medical  Journal  Editors  (see  here),  all  clinical  trials  in  British  Journal  of  Anaesthesia  must  be  
registered  in  a  public  trials  registry  at  or  before  the  onset  of  participant  enrollment.  This  
requirement  applies  to  all  clinical  trials  that  begin  enrollment  after  1  January  2009.  For  trials  that  
began  enrollment  before  1  January  2009,  registration  is  strongly  recommended  and  if  the  trial  
reported  was  not  registered,  please  comment  on  this  matter  in  the  covering  letter.  
Research  is  considered  to  be  a  clinical  trial  if  it  involves  prospective  assignment  of  human  
subjects  to  an  intervention  or  comparison  group  to  study  the  relation  between  a  health-­related  
intervention  and  a  health  outcome.  Further  details  of  which  clinical  trials  are  covered  by  this  
policy  are  in  the  updated  ICMJE  guidelines  available  here.  
The  registry  must  be  accessible  to  the  public  at  no  charge,  searchable,  open  to  all  prospective  
registrants,  and  managed  by  a  not-­for-­profit  organization.  The  registry  must  include  the  following  
information:  a  unique  identifying  number,  a  statement  of  the  intervention(s),  study  hypothesis,  
definition  of  primary  and  secondary  outcome  measurements,  eligibility  criteria,  target  number  of  
subjects,  funding  source,  contact  information  for  the  principal  investigator,  and  key  dates  
(registration  date,  start  date,  and  completion  date).  The  following  registries  are  recommended  by  
ICMJE:  Clinical  Trials,  ISRCTN  Register,  UMIN  Clinical  Trials  Registry,  Australia  New  Zealand  
Clinical  Trials  Registry,  Nederlands  Trial  Register.  
In  accordance  with  the  ICMJE’s  recommendation,  British  Journal  of  Anaesthesia  will  also  accept  
registration  of  clinical  trials  in  any  of  the  primary  registers  that  participate  in  the  World  Health  
Organization’s  International  Clinical  Trial  Registry  Platform  (see  here  ).  Primary  registers  are  
WHO  selected  registers  managed  by  not-­for-­profit  entities  that  will  accept  registrations  for  any  
interventional  trials,  delete  duplicate  entries  from  their  own  register,  and  provide  data  directly  to  
the  WHO.  Please  note  that  registration  in  any  WHO  partner  register  is  insufficient.  
Authors  are  requested  to  provide  the  exact  URL  and  unique  identification  number  for  the  trial  
registration  at  the  time  of  submission.  This  information  will  be  published  in  the  article  and  we  ask  
that  you  include  the  URL  and  identification  number  on  the  title  page  of  your  manuscript.  
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Clinical  trial  reports  should  also  comply  with  the  Consolidated  Standards  of  Reporting  Trials  
(CONSORT)  and  include  a  flow  diagram  presenting  the  enrollment,  intervention  allocation,  
follow-­up,  and  data  analysis  with  number  of  subjects  for  each  (see  here).  Please  also  refer  
specifically  to  the  CONSORT  Checklist  of  items  to  include  when  reporting  a  randomized  clinical  
trial.  
Results  posted  in  the  same  clinical  trials  registry  in  which  the  primary  registration  resides  will  not  
be  considered  prior  publication  if  they  are  presented  in  the  form  of  a  brief  abstract  (500  words  or  
less)  or  a  table.  
RESEARCH  USING  ANIMALS  
Institutional  approval    
Studies  that  involve  the  use  of  animals  must  clearly  indicate  that  Institutional  approval  was  
obtained  and  state  the  UK  Home  Office  Licence  number  or  local  equivalent  that  the  studies  were  
performed  under.  It  is  recognized  that  animal  welfare  legislation  can  vary  between  countries  and  
so  the  BJA  uses  the  UK  standards  as  a  baseline  and  reserves  the  right  to  reject  manuscripts  
judged  not  to  meet  these  standards,  even  when  local  approval  has  been  granted.  
Anaesthesia    
The  methods  of  anaesthesia  and  analgesia  for  research  studies  involving  animals  should  be  the  
best  available  to  ensure  the  welfare  of  the  animals  involved.  Reducing  the  potential  for  pain  and  
distress  is  a  significant  refinement  and  provision  of  safe  and  effective  anaesthesia  that  does  not  
interfere  with  specific  research  objectives  also  reduces  the  numbers  of  animals  used.  Authors  
must  also  state  how  they  assessed  and  monitored  the  adequacy  of  anaesthesia.    
Some  anaesthetics  may  have  interactions  that  are  important  to  certain  areas  of  research.  For  
example  medetomidine  and  xylazine  both  cause  hyperglycaemia,  osmotic  diuresis,  and  effects  
on  the  cardiovascular  system.  When  used  in  conjunction  with  ketamine,  these  agents  both  
produce  surgical  anaesthesia  in  rodents,  suitable  for  a  range  of  different  operative  procedures.  
However  the  side-­effects  may  make  them  unsuitable  for  certain  types  of  research.  The  safe  
dose  of  intra-­peritoneal  pentobarbital  in  rats  has  a  narrow  range  and  unpredictable  duration;;  
indeed  a  larger  dose  is  often  used  for  killing  an  animal  at  the  end  of  a  procedure.  Whichever  
agent  is  used,  an  appropriate  plane  of  anaesthesia  for  the  intervention  must  be  assessed  and  
achieved.  This  is  particularly  important  when  neuromuscular  blocking  agents  are  used.  
Information  on  potentially  suitable  anaesthetic  regimens  can  be  obtained  from  a  variety  of  
sources,  including  the  veterinary  advisor  at  your  research  institution,  specialist  laboratory  animal  
anaesthesia  and  general  veterinary  anaesthesia  textbooks.  Obtaining  information  on  potential  
interactions  with  research  procedures  is  less  easy  to  obtain  and  frequently  requires  a  careful  
literature  search.  The  agents  available  and  the  techniques  for  their  administration  are  evolving  
so  selecting  the  method  used  in  other  scientific  publications  will  not  guarantee  the  most  
appropriate  method.  The  choice  of  anaesthetic  and  route  of  administration  should:    
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•  Provide  the  required  depth  and  duration  of  anaesthesia  for  the  procedure    
•  Be  simple  to  administer,  without  distress  to  the  animal    
•  Should  be  free  from  undesirable  side  effects  and  allow  uncomplicated  recovery    
•  Should  cause  the  minimum  of  interference  with  the  purpose  of  the  research  procedure  
Analgesia    
When  animals  are  used  in  biomedical  research,  every  effort  should  be  made  to  minimise  any  
pain  or  distress.  Not  only  is  this  important  for  ethical  reasons,  but  also  because  pain  is  a  source  
of  stress  that  can  cause  undesirable  effects  on  the  outcome  of  research  projects.  Considerable  
progress  has  been  made  over  the  last  10-­15  years  in  preventing  or  alleviating  pain.  In  particular,  
there  is  now  considerable  opportunity  to  minimise  or  eliminate  pain  following  surgical  
procedures.  A  wide  range  of  analgesics  are  available,  and  it  is  a  simple  process  to  administer  
one  of  these  agents  to  prevent  or  alleviate  postoperative  pain.  It  is  also  important  to:    
•  Administer  an  appropriate  analgesic  that  provides  the  required  intensity  of  pain  relief    
•  Administer  the  analgesic  at  an  appropriate  dose    
•  Continue  its  administration  at  appropriate  time  intervals    
•  Stop  administering  the  analgesic  at  an  appropriate  time  after  surgery  
Provision  of  effective  pain  relief  requires  that  all  of  these  points  are  addressed,  but  this  can  only  
be  done  by  assessing  the  degree  of  pain  experienced  by  the  animal  involved.  Animal  pain  
assessment  is  difficult  and  time-­consuming  to  implement  effectively,  so  that  it  is  tempting  to  
simply  give  all  animals  a  "standard  dose"  of  analgesic.  In  man,  the  use  of  such  fixed  dose  
regimens  has  been  identified  as  one  of  the  factors  contributing  to  inadequate  pain  management,  
so  this  approach  should  be  avoided  when  dealing  with  laboratory  animals.  
In  humans,  analgesic  dose  rates  are  based  on  clinical  trials,  using  well-­established  methods  of  
assessing  pain.  In  animals,  we  are  unable  to  assess  the  severity  of  many  types  of  pain  
accurately.  Often,  all  that  is  possible  is  to  use  dose  rates  that  have  been  established  to  be  safe  
and  effective  in  some  of  the  tests  used  in  rodents  during  early  drug  development.  Provided  these  
limitations  are  appreciated,  there  are  some  strategies  for  pain  management  which  make  best  
use  of  our  existing  knowledge:    
•  If  methods  of  pain  assessment  have  been  developed  for  the  species  used,  then  these  should  
be  adapted  to  the  requirements  of  the  particular  research  procedure  being  undertaken    
•  If  methods  of  pain  assessment  are  not  available,  consider  devoting  resources  to  developing  
some  form  of  scoring  system    
•  If  pain  scoring  is  not  possible,  determine  the  analgesic  protocol  based  on  clinical  experience  
with  other  surgical  procedures  in  that  species    
•  If  possible,  use  dose  rates  that  have  been  established  using  studies  that  have  employed  pain  
scoring  systems    
•  Use  pre-­emptive  analgesia  and  consider  using  several  analgesic  agents    
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•  Attempt  to  evaluate  the  efficacy  of  the  analgesic  regimen  selected  using  clinical  assessment  
(your  veterinary  advisor  will  be  able  to  help  you  to  recognise  pain  in  laboratory  animals)    
•  Prepare  a  rescue  analgesia  protocol  and  an  immediate  euthanasia  protocol  for  animals  which  
appear  to  be  in  severe  pain  
The  use  of  animal  models  of  pain  to  investigate  analgesia  techniques  is  a  particular  minefield  for  
journals  in  the  field  of  anaesthesia.  Such  studies  must  be  conducted  with  extremely  careful  
regard  to  animal  welfare.  Rarely  will  this  journal  publish  studies  where  an  analgesic  agent  has  
been  compared  to  a  placebo  in  an  animal  model  of  severe  pain.    
The  book  ‘Laboratory  animal  anaesthesia’  by  Professor  Paul  Flecknell  (3rd  Edition,  2009,  
Academic  Press)  provides  a  very  helpful  introduction  for  research  workers  for  safe,  effective  and  
appropriate  anaesthesia  and  analgesia  in  animals  used  in  research  studies.  
Euthanasia    
Euthanasia  is  defined  as  a  pain-­free  or  stress-­free  death  and  animals  used  for  research  are  
usually  euthanized  at  the  end  of  a  study  for  the  purpose  of  sample  collection  or  post-­mortem  
examination.  Animals  may  also  be  killed  because  they  are  experiencing  severe  pain  or  distress.  
The  method  of  killing  the  animal  after  the  experiment  is  completed  should  be  chosen  carefully  
and  must  be  detailed  in  manuscripts.  The  method  used  should  be  appropriate  to  the  species  and  
the  method  used  should  not  confound  any  objective  of  the  research  -­  veterinary  advice  should  
be  sought.  The  conduct  of  euthanasia  for  those  working  with  laboratory  animals  in  the  UK  is  
quite  straightforward.  Either  the  Code  of  Practice  for  the  Humane  Killing  of  Animals  under  
Schedule  1  to  the  Animals  (Scientific  Procedures)  Act  1986  is  followed  or  a  project  and  personal  
licence  authorisation  is  obtained  to  use  a  technique  not  covered  by  this  Code.  An  updated  code  
of  practice  for  schedule  1  killing  has  been  published  by  the  Animal  Procedures  Committee  and  is  
available  online  at:    
http://apc.homeoffice.gov.uk/reference/schedule-­1-­report.pdf  
The  use  of  carbon  dioxide  for  killing  is  a  subject  of  much  debate  and  is  not  suitable  for  rabbits.  
For  rodents,  the  use  of  carbon  dioxide  is  still  permitted  but  other  methods  are  preferable.  When  
carbon  dioxide  is  used,  do  not  pre-­fill  the  cage  or  chamber  with  carbon  dioxide  and  use  slow  
filling  rates  to  minimise  discomfort.  The  flow  rate  can  be  increased  when  the  animal  is  
unconscious.  
ARRIVE  guidelines    
The  contribution  of  animal  research  in  enabling  better  health  for  man  and  animals  is  
incontrovertible  and  the  BJA  is  committed  to  the  publication  of  research  studies  which  use  
animal  models,  but  demands  the  same  rigorous  attention  to  detail  as  in  clinical  trials.  Failure  to  
describe  research  methods  and  to  report  results  appropriately  has  scientific  and  ethical  
implications  for  the  entire  research  process  and  the  reputation  of  those  involved  in  it.    
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Experiments  involving  animals  should  be  appropriately  designed,  correctly  analysed  and  then  
transparently  reported,  to  both  increase  the  validity  of  the  results,  and  maximise  the  scientific  
gain.  A  minimum  amount  of  relevant  information  must  be  included  in  manuscripts  published  in  
this  journal  to  ensure  that  the  methods  and  results  of  a  study  can  be  reviewed,  analysed  and  
repeated.  The  BJA  will  therefore  refer  to  the  ARRIVE  (Animals  in  Research:  Reporting  In  Vivo  
Experiments)  guidelines  as  the  basis  for  the  process  of  reviewing  manuscripts  of  research  
involving  animals.    
These  guidelines  were  generated  by  The  National  Centre  for  the  Replacement,  Refinement  and  
Reduction  of  Animals  in  Research,  which  is  an  independent  scientific  organisation,  established  
by  the  UK  Government,  in  consultation  with  scientists,  statisticians,  journal  editors  and  research  
funders.  
ANAESTHESIA  
Descriptions  of  methods  of  anaesthesia  are  often  unnecessarily  cumbersome.  The  following  
model  is  presented  as  an  example  of  economy  of  words:  The  patients  did  not  receive  
premedication.  Anaesthesia  was  induced  with  propofol  2  mg  kg  -­1  and  fentanyl  1.5  μg  kg  -­1  .  
Vecuronium  0.1  mg  kg  -­1  was  given  to  facilitate  orotracheal  intubation  with  a  cuffed  tube.  
Anaesthesia  was  maintained  with  sevoflurane  1.5-­2.0%  and  nitrous  oxide  60%  in  oxygen,  with  
positive  pressure  ventilation  in  a  circle  system.  A  similar  description  should  be  used  for  animal  
anaesthesia.  
STATISTICAL  ANALYSIS  
Statistical  methods  must  be  described  with  enough  detail  to  enable  a  knowledgeable  reader  with  
access  to  the  original  data  to  verify  the  report  and  results.  Where  possible,  findings  should  be  
quantified  and  presented  with  appropriate  indicators  of  measurement  error  or  uncertainty  (such  
as  confidence  intervals).  Confidence  intervals  provide  a  more  informative  way  to  deal  with  a  
significance  test  than  a  simple  P  value.  A  power  analysis  should  be  performed  before  starting  
the  study  to  determine  the  number  of  subjects  which  need  to  be  studied  in  each  group  to  detect  
a  given  change.  Please  note  that  a  power  analysis  based  on  the  primary  end-­point  will  not  
necessarily  be  applicable  to  any  secondary  measures.  
It  is  recommended  that  authors  seek  appropriate  statistical  advice  before  starting  their  study,  to  
ensure  that  the  structure  and  planned  recruitment  is  adequate  to  answer  the  question  set.  
RESULTS  
Guidance  for  this  section  includes;;    
•  Must  be  factual    
•  Relate  to  aims    
•  Logical  order    
•  State  significances    
•  Negative  findings  
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From  January  2009,  all  randomized  control  trials  (RCTs)  must  adhere  to  the  Consort  guidelines  
and  present  a  flow  diagram  which  details  the  conduct  of  the  study  (  http://www.consort-­
statement.org/)  
Description  of  experimental  results  should  be  concise.  They  should  be  presented  in  a  factual  
manner  and  related  to  the  aim  of  the  study.  It  is  often  useful  to  present  the  results  in  the  order  
described  in  the  Methods  section.  Data  should  not  be  repeated  unnecessarily  in  text,  tables  and  
figures  (see  below),  and  unwarranted  numbers  of  digits  should  be  avoided  (Example:  the  mean  
dose  of  propofol  was  2.1  mg  kg  -­1  rather  than  2.0897  mg  kg  -­1  ).  It  may  not  be  necessary  to  
provide  all  the  data  from  a  complex  study:  only  those  values  which  are  essential  to  the  
communication  should  be  given.  However,  results  should  be  presented  in  a  manner  so  that  the  
reader  can  check  the  statistical  inferences.  If  the  data  are  so  numerous  that  this  is  not  possible,  
the  editor  must  be  sent  a  full  set  with  the  submission  of  the  original  manuscript  and  the  readers  
should  be  informed  as  to  where  they  can  obtain  a  similar  full  set  of  results.  Where  appropriate,  
for  example  in  a  pharmacokinetic  study,  more  extensive  sets  of  data  can  be  included  as  an  
appendix  with  the  on-­line  version  of  the  article.  If  authors  wish  to  make  use  of  this  facility,  they  
should  state  this  in  the  submission  letter  and  upload  the  data  as  a  separate  file.  The  editor  has  
the  right  to  request  the  original  data  collected.  In  the  results  section  there  should  be  no  attempt  
at  a  discussion  of  the  findings.  
TABLES  AND  FIGURES  
Figures  and  Tables  are  often  useful  to  present  either  complex  or  extensive  data  in  a  more  easily  
understandable  form.  However,  authors  are  cautioned  against  unnecessary  use  of  tables  and  
figures.  A  useful  approach  is  to  prepare  the  raw  data  in  the  form  of  tables  and  then  decide  which  
data  are  to  be  presented  in  the  article.  The  author  should  then  decide  whether  the  essential  data  
be  presented  succinctly  in  the  text.  If  not,  the  essential  tables/  figures  should  be  prepared.  To  
illustrate  this  with  examples:  a  study  outcome  which  compares  two  measurements  in  two  groups  
can  easily  be  presented  as  text,  a  comparison  of  arterial  pressure  and  heart  rate  changes  at  five  
timepoints  in  two  groups  would  be  appropriate  as  a  table  and  the  same  measurements  in  
comparing  three  groups  may  be  better  as  a  figure.  
Tables  and  figures  are  important  communications  and  should  be  accompanied  by  a  legend  
which  makes  it  self-­explanatory.  However,  the  legend  must  not  contain  experimental  details,  
which  should  be  given  in  the  methods  section.  
The  use  of  a  figure  should  be  considered  only  where  a  figure  will  present  the  data  more  clearly  
than  is  possible  in  a  table  or  when  an  important  trend  or  comparison  has  to  be  made  for  which  a  
graphic  presentation  is  clearly  superior  to  a  table  or  text.  
The  authors  should  decide  which  form  they  wish  to  present  data  in.  Please  note  the  limitation  
given  above  on  the  number  of  figures/tables  permissible  for  each  article  type.  Duplication  of  data  
by  including  it  as  a  table  and  as  a  figure  is  unnecessary  and  wasteful.  
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Authors  are  advised  to  note  the  limitation  on  the  number  of  figures/tables  given  above  (4-­6  
tables  or  figures,  in  total)  for  clinical  and  laboratory  investigations  and  1  figure  or  table  for  a  case  
report  or  editorial.  The  use  of  multiple  small  figures  submitted  as  one  figure  (for  example  Figure  
1  a-­f)  is  discouraged  as  when  reduced  to  printed  size  these  may  not  be  clear.  Authors  are  
strongly  advised  to  be  selective  in  their  use  of  figures  and  tables.  
For  further  guidance  on  the  format  of  tables  and  figures,  see  below.  It  is  recommended  that  the  
author  refers  to  previous  issues  of  the  journal  regarding  appropriate  style.  
DISCUSSION  
This  is  an  important  part  of  the  manuscript  but  it  should  not  be  too  long,  perhaps  one  third  of  the  
total  length  of  the  paper.  This  requires  discipline  by  the  author  for  two  reasons:  first,  they  may  
feel  that  the  task  is  nearly  completed  and  that  they  are  subject  to  fewer  constraints;;  second,  
many  authors  seem  to  wish  to  read  into  their  data  more  than  is  actually  there.    
It  is  suggested  that  the  discussion  should  normally  follow  the  pattern  below:  
•  State  main  findings    
•  How  do  they  fit  in  with  previous  studies    
•  Why  are  they  different  /  same    
•  What  it  adds  to  knowledge  of  subject    
•  Weaknesses  in  study    
•  Future  studies    
•  Conclusions  
State  main  findings    
This  does  not  mean  a  repetition  of  all  the  results  with  their  statistics.  It  should  provide  a  concise  
overview  of  the  study.  For  example,  '  Drug  X  produced  a  greater  haemodynamic  change  on  
induction  of  anaesthesia  than  occurred  with  drug  Y,  resulting  in  a  greater  fall  in  arterial  pressure  
and  a  higher  incidence  of  tachycardia  '.  
How  do  they  fit  in  with  previous  studies    
This  section  should  relate  directly  to  the  statements  made  in  the  Introduction  and  qualify  you  
finding  in  relation  to  the  previous  studies  of  the  subject.  For  example,  mention  any  important  
uncertainties  in  the  methods  of  measurement.  In  laboratory  studies,  try  to  relate  the  
concentrations  used  to  those  encountered  clinically.  
Why  are  they  different  /  same    
Deductions  which  may  explain  important  differences  between  the  data  of  the  present  study,  and  
the  data  of  previous  studies.  The  author  should  avoid  excessive  speculation  in  this  section.  It  is  
quite  reasonable  to  suggest  possible  explanations  for  your  findings  and  any  differences  from  
previous  studies  but  the  'missing  parts'  of  such  reasoning  must  be  acknowledged.  
What  it  adds  to  knowledge  of  subject    
This  can  summarise  the  previous  sections  by  pulling  together  the  implications  of  your  main  
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findings,  studies  by  other  workers  and  their  combined  contribution  to  our  knowledge  of  the  
subject.  This  should  not  be  just  another  repetition  of  the  results  and  preceding  discussion  but  
more  of  an  expanded  conclusion.  
Weaknesses  in  study    
It  is  appropriate  to  briefly  acknowledge  any  limitations  of  your  study  at  this  point.  Examples  here  
could  include  the  patient  population,  limitations  of  analytical  tests,  patients  lost  to  follow-­up.  
Authors  are  advised  to  be  honest  but  succinct  in  this  section.  
Future  studies    
A  logical  follow  on  to  the  two  previous  sections  is  to  identify  future  studies  that  would  address  
some  of  the  potential  explanations  and  limitations  discussed  earlier.  This  should  again  be  
concise.  An  extensive  list  of  future  studies  undermines  you  own  study:  i.e.  has  it  answered  
anything  if  there  are  still  so  many  questions?  
Conclusions    
Conclusions  from  the  present  study.  The  original  contribution  to  knowledge  from  the  present  
study  is  stated.  A  common  fault  here  is  to  overstate  the  findings  from  a  study.  For  example,  if  
you  have  studied  the  effect  of  a  new  drug  in  an  animal  model  you  cannot  draw  any  conclusions  
at  all  about  its  effect  in  humans  and  likewise  if  you  studied  ASA  1  and  2  patients  you  cannot  
comment  on  its  use  in  critically  ill  patients.    
It  may  be  appropriate  to  give  the  implications  of  the  conclusions  for  anaesthetic  practice  and  the  
indications  for  further  enquiry  in  this  area  of  interest.    
Authors  should  remember  at  all  times,  but  especially  in  writing  the  discussion,  that  they  will  spoil  
their  manuscript  by  excessive  length.  A  discussion  of  more  than  three  pages  is  often  too  long.  
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ILLUSTRATIONS  AND  FIGURES  
As  the  journal  is  now  printed  in  full  colour,  there  is  no  charge  to  authors  for  colour  reproduction.  
It  can  help  avoid  delays  in  publication  if  line  drawings  are  supplied  using  the  journal's  agreed  
colour  palette:    
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Colour  1  (blue):  c100  m57  y0  k2    
Colour  2  (green):  c71  m26  y100  k25    
Colour  3  (Pink):  c10  m70  y0  k0    
Colour  4  (gold):  c0  m50  y100  k0    
Colour  5  (light  blue):  c80  m0  y0  k0    
Colour  6  (orange):  c0  m80  y100  k0    
It  should  be  borne  in  mind  that  reduction  of  figures  results  in  an  accompanying  reduction  of  
boldness  (thickness)  of  all  parts  of  the  figure.  It  is  thus  inappropriate  to  use  a  variety  of  boldness  
of  axes,  graph  lines  and  lettering  in  one  figure,  or  to  present  a  figure  drawn  to  a  large  scale  in  
fine  lines  and  with  small,  fine  lettering.  The  problem  of  computer-­produced  diagrams  may  be  
obviated  by  programming  the  computer  to  produce  a  diagram  of  the  same  size  as  that  of  the  
final  published  diagram  or,  alternatively,  to  produce  lines  and  lettering  of  large  thickness  so  that  
photoreduction  results  in  the  appropriate  size.  Photographs  and  micrographs  should  be  
annotated.  
Care  should  be  taken  that  the  labelling  of  axes  does  not  extend  the  dimensions  of  the  figure  
substantially.  Avoid  suppression  of  the  zero  point  (the  axes  may  be  broken(/  /)  if  required).  (See  
also  Units,  symbols  and  abbreviations  below).  It  should  be  emphasized  that  the  dimensions  of  a  
figure  prepared  for  a  slide  are  often  unsuitable  for  reproduction  on  the  printed  page.  Symbols  
which  are  to  appear  in  the  figure  (and  not  in  the  legend)  should  be  chosen  from  the  examples  
shown  below:    
●  ○  ■  嘋  ▼  ▲  ♦  ◊  V  X  +    
Symbols  should  be  explained  in  boxed  key  included  in  the  figure.    
Accuracy  in  the  preparation  of  figures  is  essential  as  is  the  appropriate  use  of  symbols  and  
abbreviations  (see  below).  
Line  drawings  should  be  of  a  resolution  of  at  least  600  dpi  and  half-­tones  at  least  300  dpi.    
Full  instructions  for  the  preparation  of  figures  are  available  in  the  Online  submission  instructions  
page.  
Third-­Party  Content  in  Open  Access  papers  
If  you  will  be  publishing  your  paper  under  an  Open  Access  licence  but  it  contains  material  for  
which  you  do  not  have  Open  Access  re-­use  permissions,  please  state  this  clearly  by  supplying  
the  following  credit  line  alongside  the  material:    
Title  of  content   Author,  Original  publication,  year  of  original  publication,  by  permission  of  [rights  
holder]    This  image/content  is  not  covered  by  the  terms  of  the  Creative  Commons  licence  of  
this  publication.  For  permission  to  reuse,  please  contact  the  rights  holder.  
VIDEOS  
Videos  can  now  be  published  in  the  online  article  with  a  still  image  of  the  video  appearing  in  the  
 71 
print  version.  Authors  should  submit  videos  in  MP4  format  according  to  our  video  submission  
guidelines.  Still  images  to  be  used  in  the  article  need  to  be  provided  and  should  represent  as  
best  as  possible  the  main  subject  of  the  video.  Video  files  should  be  clearly  named  as  video  1,  
video  2  etc,  and  still  images  should  be  named  ‘video  1  still  image’.  Any  supplementary  videos  
that  should  not  be  published  in  the  article  should  be  uploaded  as  supplementary  data.    
All  videos  should  have  an  accompanying  legend.  
UNITS,  SYMBOLS  AND  ABBREVIATIONS  
The  British  Journal  of  Anaesthesia  uses  the  SI  system  of  units  with  a  few  notable  exceptions  (pH  
and  intravascular  and  ventilatory  pressure  measurements,  which  should  be  given  in  units  of  
calibration,  e.g.  mm  Hg,  cm  H  2  O).  Blood-­gas  tensions  and  the  partial  pressures  in  the  gas  
phase  should  be  given  in  the  appropriate  SI  unit  (kPa  for  kilopascal).  It  is  not  intended  to  give  a  
detailed  account  of  the  SI  system,  the  notation  of  units,  symbols  and  abbreviations  in  this  
document.  Readers  are  referred  to  Units,  Symbols  and  Abbreviations.  A  Guide  for  Biological  and  
Medical  Editors  and  Authors  ,  4th  Edn.  Baron  DN,  ed.  (1988),  published  by  and  available  from  
the  Royal  Society  of  Medicine,  1  Wimpole  Street,  London  W1M  8AE.  
Particular  problems  have  arisen  in  relation  to  the  notation  of  units  which  was  introduced  at  the  
same  time  as  the  change  to  the  SI  system.  Avoid  the  use  of  the  solidus  (/)  in  favour  of  various  
units  of  the  expression  set  on  one  line.  In  the  case  of  expressions  'below  the  line'  superscript  -­1,  
-­2,  etc.  as  appropriate  is  given.  Thus  for  drug  dosage  use  mg  kg  -­1  not  mg/kg.  
SPELLING  AND  GRAMMAR  
Standard  Oxford  UK  English  should  be  used.  Examples:  anaesthesia,  haemorrhage,  
organization.  
CORRESPONDENCE  
Each  issue  of  the  journal  will  contain  correspondence  (Letters  to  the  Editor).  We  attempt  to  
publish  correspondence  arising  from  papers  in  a  recent  issue  with  the  minimum  of  delay,  and  for  
this  reason  such  correspondence  will  be  given  priority.  The  Editor  may  change,  delete  or  modify  
in  any  way  all  items  of  correspondence.  
Correspondence  relating  to  a  recently  published  article    
Correspondence  relating  to  a  recently  published  article  should  be  submitted  electronically  
through  our  'eletters'  facility.  This  can  be  accessed  through  the  BJA  website.  Correspondents  
should  access  the  relevant  article  on  this  site  and  use  the  'submit  an  eletter  about  this  article'  
button.  This  is  the  only  route  for  submission  of  correspondence  relating  to  published  articles.  
Readers  submitting  a  letter  by  post  or  email  to  the  editor  relating  to  a  published  article  will  be  
directed  to  submit  them  electronically.  
The  advantage  of  the  eletter  facility  is  that  letters  from  readers  are  put  on-­line  within  a  few  days  
of  submission.  When  an  eletter  is  put  on-­line  the  author  of  the  original  article  automatically  
receives  notification  that  a  comment  has  been  submitted  and  is  invited  to  respond  promptly.  The  
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eletters  are  checked  regularly  and  selected  eletters  are  published  subsequently  in  the  Journal.  
Correspondence  not  related  to  a  published  article    
Correspondence  which  does  not  relate  to  a  published  article  may  be  submitted  either  as  an  
eletter  using  the  'out  of  the  blue'  system  on  the  BJA  website  or  as  an  email  attachment  to  the  
Editor-­in-­chief.  This  includes  studies  that  have  had  a  'submit  as  a  letter'  decision,  case  
descriptions  or  topics  of  general  interest.  Correspondence  may  also  be  submitted  by  mail  on  a  
disk  directly  to  the  Editor-­in-­Chief.  All  authors  must  sign  the  accompanying  submission  letter.  
Authors  should  provide  a  contact  E-­mail  and  fax  number.  The  eletters  are  checked  regularly  and  
selected  eletters  are  published  subsequently  in  the  Journal.  
PROOFS  
These  should  be  downloaded  from  the  online  proofing  system,  corrected  and  returned  to  the  
publisher  by  uploading  them  to  the  online  site  within  3  working  days  of  receipt.  
REPRINTS  
On  publication,  the  corresponding  author  will  be  sent  the  URL  for  online  access  to  their  article.  
Offprints  and  single  issues  can  be  ordered  using  the  Oxford  Journals  Author  Services  site.  
Orders  from  the  UK  will  be  subject  to  the  current  UK  VAT  charge.  For  orders  from  elsewhere  in  
the  EU  you  or  your  institution  should  account  for  VAT  by  way  of  a  reverse  charge.    Please  
provide  us  with  your  or  your  institution’s  VAT  number.  
AUTHOR  SELF-­ARCHIVING/PUBLIC  ACCESS  POLICY  FROM  MAY  2005  
For  information  about  this  journal's  policy,  please  visit  our  Author  self-­archiving  policy  
ONLINE  LICENCE  
Upon  receipt  of  accepted  manuscripts  at  Oxford  Journals  authors  will  be  invited  to  complete  an  
online  copyright  licence  to  publish  form.    
Please  note  that  by  submitting  an  article  for  publication  you  confirm  that  you  are  the  
corresponding/submitting  author  and  that  Oxford  University  Press  ('OUP')  may  retain  your  email  
address  for  the  purpose  of  communicating  with  you  about  the  article.  Please  notify  OUP  
immediately  if  your  details  change.  If  your  article  is  accepted  for  publication  OUP  will  contact  you  
using  the  email  address  you  have  used  in  the  registration  process.  Please  note  that  OUP  does  
not  retain  copies  of  rejected  articles.  
OPEN  ACCESS  
British  Journal  of  Anaesthesia  authors  have  the  option  to  publish  their  paper  under  the  Oxford  
Open  initiative;;  whereby,  for  a  charge,  their  paper  will  be  made  freely  available  online  
immediately  upon  publication.  After  your  manuscript  is  accepted  the  corresponding  author  will  be  
required  to  accept  a  mandatory  licence  to  publish  agreement.  As  part  of  the  licensing  process  
you  will  be  asked  to  indicate  whether  or  not  you  wish  to  pay  for  open  access.  If  you  do  not  select  
the  open  access  option,  your  paper  will  be  published  with  standard  subscription-­based  access  
and  you  will  not  be  charged.  
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Oxford  Open  articles  are  published  under  Creative  Commons  licences.    
RCUK/Wellcome  Trust  funded  authors  publishing  in  the  British  Journal  of  Anaesthesia  can  use  
the  Creative  Common  Attribution  licence  (CC  BY)  for  their  articles.    
All  other  authors  can  use  the  following  Creative  Commons  licence:    
•  Creative  Commons  Attribution  Non-­Commercial  licence  (CC  BY-­NC)    
Please  click  here  for  more  information  about  the  Creative  Commons  licences.  
OPEN  ACCESS  CHARGES  
You  can  pay  Open  Access  charges  using  our  Author  Services  site.  This  will  enable  you  to  pay  
online  with  a  credit/debit  card,  or  request  an  invoice  by  email  or  post.  The  open  access  charges  
are  as  follows.    
•  Regular  charge:  £2000/  $3200  /  €2600    
•  Reduced  Rate  Developing  country  charge*:  £1000/  $1600  /  €1300    
•  Free  Developing  country  charge*:  £0  /$0  /  €0    
*Visit  our  developing  countries  page  (click  here  for  a  list  of  qualifying  countries).    
Please  note  that  these  charges  are  in  addition  to  any  colour  charges  that  may  apply.  
BRITISH  JOURNAL  OF  ANAESTHESIA  POLICIES  
This  section  articulates  the  policies  which  are  followed  by  the  journal  in  its  editorial  process.  The  
policies  are  based  on  the  recommendations  by  International  Committee  of  Medical  Journal  
Editors.  
ADVERTISING  
The  editorial  decisions  of  British  Journal  of  Anaesthesia  are  taken  separately  from,  and  not  
influenced  by,  advertising  or  any  related  revenue.  The  journal  makes  all  possible  efforts  to  
refuse  advertisements  which  are  misleading.  The  publication  of  an  article  about  a  product,  
alongside  an  advertisement  of  the  product,  if  it  occurs,  is  purely  co-­incidental.  
COMPLAINTS  
The  authors  who  may  have  a  complaint  against  any  of  the  aspects  of  their  interaction  with  British  
Journal  of  Anaesthesia  should,  in  the  first  instance,  write/e-­mail  to  the  Editor  responsible  for  
handling  the  manuscript.  In  case  it  does  not  resolve  the  issue,  the  complaint  should  be  
forwarded  to  the  Editor-­in-­Chief.  The  Editors  and  Editor-­in-­Chief  aim  to  acknowledge  the  
complaint  within  7  days  after  receiving  it.  In  addition,  they  should  explain  to  the  author  the  
procedure  which  they  will  be  undertaking  to  resolve  the  matter.  
CORRECTIONS  
If  the  errors  are  noted  in  an  article  published  in  an  issue,  and  these  require  publication  of  a  
correction,  the  corrections  will  appear  on  a  numbered  page  and  be  listed  in  the  Table  of  
Contents.  
MANUSCRIPTS  AUTHORED  BY  A  MEMBER  OF  EDITORIAL  BOARD  
The  manuscripts  which  are  authored  by  Editors,  or  members  of  Editorial  Board,  are  treated  no  
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differently  to  any  other  manuscript  submitted  to  British  Journal  of  Anaesthesia  .  All  possible  
measures  are  undertaken  to  avoid  any  potential  conflict  of  interest  in  handling  of  such  
manuscripts  at  all  the  stages  including  allocation  of  handling  editor,  selection  of  reviewers,  
decision  making  and,  if  required,  processing  for  publication.  
MEDIA  RELEASE  
Authors  should  not  release  stories  related  to  their  work  prior  to  publication  of  their  paper  in  the  
journal.  If  authors,  and/or  editors,  consider  particular  work  suitable  for  media  release,  they  
should  discuss  it  among  themselves,  and  agree  on  a  planned  media  release  and  publication.  In  
case  of  agreed  media  release,  the  editors  will  plan  with  the  authors  the  way  in  which  they  can  
help  the  media  in  preparing  accurate  reports  by  providing  news  releases,  answering  questions,  
or  referring  reporters  to  relevant  experts.  This  assistance  will  be  contingent  on  the  media’s  
cooperation  in  timing  the  release  of  a  story  to  coincide  with  publication  of  the  article.  
MISCONDUCT/RETRACTIONS  
All  the  manuscripts  submitted  to  British  Journal  of  Anaesthesia  undergo  plagiarism  check  using  
commercial  software.  Based  on  the  findings  of  the  check,  editors  may  ask  authors  to  address  
any  minor  duplication,  or  similarity,  which  the  contents  of  their  manuscript  may  have  to  
any  previously  published  work  (  even  though  it  may  be  author’s  own  previously  published  work).  
However,  severe  cases  of  plagiarism  amount  to  ‘misconduct’,  and  these  cases  will  be  dealt  with  
as  such.  
The  reviewers  and  the  editors  initially  assume  that  authors  are  reporting  work  based  on  honest  
observations.  However,  if  substantial  doubt  arises  about  the  honesty  or  integrity  of  work,  either  
submitted  or  published,  the  editor  will  inform  the  authors  of  the  concern,  seek  clarification,  and  
pursue  the  issue  with  the  author’s  sponsoring  body  and/or  employing  authority.  Consequently,  if  
the  sponsoring  body  and/or  employers  find  a  published  paper  to  be  fraudulent,  the  journal  will  
print  a  retraction.  If,  however,  this  method  of  investigation  does  not  result  in  a  satisfactory  
conclusion,  the  editor  may  choose  to  conduct  his  or  her  own  investigation,  and  may  choose  to  
publish  an  expression  of  concern  about  the  aspects  of  the  conduct  or  integrity  of  the  work.  The  
validity  of  previous  work  by  the  author  of  a  fraudulent  paper  cannot  be  assumed.  Editors  may  
ask  the  author’s  institution  to  assure  them  of  the  validity  of  earlier  work  published  in  their  journal  
or  to  retract  it.  If  this  is  not  done,  editors  may  choose  to  publish  an  announcement  expressing  
concern  that  the  validity  of  previously  published  work  is  uncertain.  
CROSSREF  FUNDING  DATA  REGISTRY  
In  order  to  meet  your  funding  requirements  authors  are  required  to  name  their  funding  sources,  
or  state  if  there  are  none,  during  the  submission  process.  For  further  information  on  this  process  
or  to  find  out  more  about  the  CHORUS  initiative  please  click  here.  
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